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“None of this had even a hope of any practical application in my life. But 10 years 
later, when we were designing the first Macintosh computer, it all came back to me. 
And we designed it all into the Mac. It was the first computer with beautiful typography. 
If I had never dropped in on that single course in college, the Mac would have never 
had multiple typefaces or proportionally spaced fonts. And since Windows just copied 
the Mac, its likely that no personal computer would have them.  
If I had never dropped out, I would have never dropped in on this calligraphy class, and 
personal computers might not have the wonderful typography that they do. Of course it 
was impossible to connect the dots looking forward when I was in college. But it was 
very, very clear looking backwards 10 years later. 
Again, you can’t connect the dots looking forward; you can only connect them looking 
backwards. So you have to trust that the dots will somehow connect in your future. You 
have to trust in something–your gut, destiny, life, karma, whatever. This approach has 
never let me down, and it has made all the difference in my life.” 
Steve Jobs, from the 2005 Stanford Commencement Address 
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Abbreviations list 
 
 
5-FU = 5-Fluorouracil 
ABD= ATPase domain 
ACT = adoptive cell transfer 
Ann V = Annexin V 
APCs = Antigen Presenting Cells 
ATP = adenosine-3-phosphate 
ARG-1= arginase-1 
BCR = B cell receptor 
BM = Bone marrow 
CDRs = complementary-determining regions 
CDs= cluster of differentiation 
cGy = centy-Gray 
Cox-2= cyclooxygenase-2 
CRT = chemoradiotherapy 
CTLA-4= cytotoxic T-lymphocytes-associated antigen 4 
CTLs = Cytotoxic T Lymphocytes 
DAMPs = danger-associated molecular patterns 
DAPI = 4',6-diamidino-2-phenylindole 
DCs = Dendritic cells 
EFS = event-free survival 
ELISA = Enzymed-Linked Immunoassorbent Assay 
ER = endoplasmatic reticulum 
FACS = fluorescence-activated cell sorting 
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FasL = Fas Ligand 
FBS = Fetal bovine serum 
GEM = gemcitabine 
GM-CSF = granulocyte-macrophage stimulating factor 
GvHD = graft versus host desease 
H&E = hematoxylin/eosin 
H-2 = hystocompatibility-2 
HIFU = high-intensity focused ultrasound 
HLA = human leucocytes antigens 
HMGB-1 = high mobility group box-1 
HSPs = Heat Shock Proteins 
HT = hyperthermia 
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i.p = intraperitoneal 
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i.v. = intravenous 
ICAM-1 = Intercellular Adhesion Molecule 1 
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IFN-γ = interferon-γ 
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M-CSF= macrophage-colony stimulating factor 
mDCs = mature Dendritic cells 
MDSCs= myeloid derived suppressor cells 
MHC-I, -II = Major Histocompatibilty Complex-I, -II 
MMP = matrix metalloproteinases 
NK = Natural Killer cells 
NOS= nitric-oxide synthase 
OS = overall survival 
PaCa = Pancreatic cancer 
PAMPs = Pathogens Associated Molecular Patterns 
PanIN = pancreatic intraepithelial neoplasia 
PB = peripheral blood 
PBD = Peptide Binding Domain 
PBMCs (hu) =  human peripheral blood mononuclear cells 
PBS = Phosphate-buffered Saline 
PDCs= plasmacytoid dendritic cells 
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PGE2 = Prostaglandin E2 
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TCR = T cell receptor 
TGF-β = Transforming Growth Factor-β 
Th1, 2, 17 = T helper cell-1, -2, -17 
TNF-α, -β = Tumor Necrosis Factor-α, -β 
TRANCE= TNF-related association-induced cytokine 
Treg = T regulatory cells 
VEGF = vascular endothelial growth factor 
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Summary 
 
Pancreatic cancer has a poor prognosis and the 5-years survival rate is less than 1%, with a 
median survival of 4–6 months. For this reason, new therapies are needed and 
immunotherapy might be an option.  
The development of a preclinical model to study in vivo the cross-talk between tumor and 
immune system can be crucial. The initial aim of this study was the reconstitution of 
newborn immunodeficient mice with intrahepatically injection of bone marrow-derived 
leukocyte precursor CD34+ cells from pancreatic cancer patients, in order to obtain 
patient-specific humanized mice, to be implanted subcutaneously or orthotopically with 
pancreatic tumor cells from the same patient; such a system should allow to study in vivo 
the cross-talk between tumor and immune system and to evaluate immunotherapeutic 
approaches in a “patient-specific setting“. Unfortunately, burocratic problems hampered so 
far the acquisition of bone marrow-derived leukocyte precursor CD34+ cells from 
pancreatic cancer patients as well as from healthy donors. Therefore, we reprogrammed the 
the study and:  
1- we established protocols of delivery of human PBMCs to C57BL/6-Rag2-/-  chain-
/-
 immunodeficient mice, starting from either newborn or adult mice; 
2-  we developed an adoptive cell transfer (ACT) therapy based on human T 
lymphocytes activated in vitro by autologous DCs loaded with necrotic pancreatic 
tumor cells after hyperthermia or UVC treatment, to be delivered to C57BL/6-
Rag2
-/-
  chain-/- mice bearing the same human pancreatic tumor from which the 
necrotic cells used for DC loading were derived. 
As expected, the reconstitution we obtained using human PBMCs regarded only the human 
T and B cells compartment, and not cells of the innate immunity. The differences observed 
in mice reconstituted by injection of human PBMCs at newborn versus mice injected at 
adult age concerned mortality and the presence of T cells in peripheral blood. Mice 
injected at newborn age showed very high mortality following injection (67%) and 
relatively low percentage of reconstituted animals (45% of alive animals). Nevertheless 
reconstituted mice presented human lymphoid cells either circulating in the blood or in 
lymphoid organs. On the contrary, mice injected with human PBMCs at adult age did not 
show any mortality effect, but the amounts of circulating human lymphoid cells in the 
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blood was very low, even if engrafment of human cells in lymphoid organs was similar to 
that found in mice injected at newborn and adult age.  
The second part of work presented is focused on the development of an immunotherapeutic 
approach for pancreatic cancer. The immunogenic potential of dying tumor cells is 
receiving great attention on account of both its importance in enhancing T-cell directed 
immunotherapy and its indication of the best immunogenic source for ex vivo TAA DCs 
loading (Lake et al., 2005; Nowak et al., 2006). DCs are potent antigen-presenting cells 
and, as recently shown, can be activated by DAMPs, such as HMGB-1 and HSP-70, that 
are highly expressed after hyperthermia treatment of cancer cells and that induce anti-
tumor immunity (Shi et al., 2006; Bianchi et al., 2007; Chen et al., 2009). Antigen 
presentation by DCs is essential to effective antitumor T cells responses in cancer patients, 
but it depends on DCs origin, maturation state and the environmental cytokine milieu. 
For this reason, we focused our attention on the activation of a tumor-protective immune 
response using human PaCa-44, PT-45, PANC-1 and PANC-2 pancreatic tumor cell lines.  
We developed an immunotherapeutic strategy based on human dendritic cells from healthy 
blood donors loaded with cancer cells in secondary necrosis due to incubation at 56°C or 
exposure to UVC.  
This immunotherapeutic approach appears promising, especially using UVC exposure as 
tumor death treatment. The treatments induced apoptosis followed by secondary necrosis 
and the release in the supernatant of levels of DAMPs much higher than without treatment. 
DAMPs are responsible for stimulation of DCs to antigen uptake and maturation, and 
consequently, for an increased immunogenity of tumor cells, as shown by the expression of 
higher levels of maturation markers such as CD80, CD83 and MHC-II. Secondary necrosis 
also resulted in an improvement of uptake efficiency by DCs for all the four different 
pancreatic cancer cell lines. The specific immune response obtained when T cells from the 
same donor as DCs were added to activated DCs according to standard protocols, was 
variable between different pancreatic cancer cell lines and it was also blood donor-
dependent: a specific immune response was obtained in vitro only against PaCa-44 and 
PT-45 cancer cell lines, and not against PANC-1 and PANC-2 cell lines. These results 
were also confirmed in vivo in a protocol of curative immunotherapy using PaCa-44 and 
PT-45 cancer cells only, even if the low number of T-lymphocytes injected and of animals 
for each groups are a crucial points for the assessment of a functional preclinical model.  
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Riassunto 
 
Il cancro al pancreas ha una prognosi scarsa e la percentuale di pazienti affetti da questa 
patologia che sopravvivono per 5 anni è inferiore all‟1%, con una sopravvivenza media che 
oscilla tra i 4 e i 6 mesi. Ecco perché sono necessarie nuove terapie, e l‟immunoterapia 
potrebbe rivelarsi un approccio terapeutico valido e promettente. 
Lo sviluppo di un modello preclinico per studiare in vivo l‟interazione tra il tumore e il 
sistema immunitario può essere cruciale. L‟obiettivo iniziale di questo studio era la 
ricostituzione di un sistema immunitario umano in topi immunodeficienti appena nati, 
mediante un‟iniezione intraepatica di cellule staminali ematopoietiche CD34+ derivate dal 
midollo osseo di pazienti affetti da cancro al pancreas, al fine di ottenere topi umanizzati 
corrispondenti al paziente, da sottoporre a impianto ortotopico o sottocutaneo di cellule 
tumorali pancreatiche prelevate dal medesimo paziente. Tale sistema dovrebbe consentire 
di studiare in vivo l‟interazione tra il tumore e il sistema immunitario e di valutare gli 
approcci immunoterapeutici più validi a seconda del diverso paziente. 
Sfortunatamente, ad oggi, i problemi burocratici hanno impedito l‟acquisizione di cellule 
precursori CD34+ derivate dal midollo osseo sia di pazienti affetti da cancro al pancreas 
sia di donatori sani. Per cui abbiamo riprogrammato il lavoro e: 
1) abbiamo messo a punto dei protocolli di ricostituzione di un sistema immunitario 
umano in topi immunodeficienti C57BL/6-Rag2
-/-
  chain-/- appena nati o adulti, 
utilizzando cellule mononucleate di sangue periferico di donatori sani (PBMCs) 
2) abbiamo sviluppato un modello di „trasferimento adottivo cellulare‟ (ACT) basato 
su linfociti T umani attivati in vitro da cellule dendritiche autologhe caricate con 
cellule necrotiche di adenocarcinoma pancreatico dopo ipertermia o trattamento 
con UVC. Questi linfociti T attivati in vitro sono stati trasferiti a topi C57BL/6-
Rag2
-/-
 chain-/- precedentemente inoculati con la stessa linea cellulare tumorale dal 
quale sono state derivate le cellule necrotiche usate nella stimolazione in vitro delle 
cellule dendritiche. 
Come previsto, la ricostituzione che abbiamo ottenuto usando cellule mononucleate di 
sangue periferico ha riguardato solo il compartimento delle cellule T e B e non le cellule 
dell‟immunità naturale. Le differenze osservate nei topi ricostituiti mediante iniezione di 
PBMCs umane alla nascita rispetto ai topi iniettati in età adulta ha riguardato la mortalità e 
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la presenza di cellule T nel sangue periferico. I topi iniettati alla nascita hanno mostrato 
un‟alta mortalità dopo il trattamento (67%) e una percentuale relativamente bassa di 
animali ricostituiti (45% sul totale degli animali rimasti in vita). Tuttavia i topi ricostituiti 
da neonati hanno presentato cellule linfoidi umane in circolo nel sangue periferico e negli 
organi linfoidi. Al contrario, i topi iniettati da adulti con PBMCs di donatori sani hanno 
mostrato un‟ottima sopravvivenza dopo il trattamento, ma la quantità di cellule linfoidi 
umane in circolo nel sangue periferico si è rivelata molto bassa; tuttavia, la presenza di 
cellule umane negli organi linfoidi era simile a quella riscontrata nei topi iniettati da 
neonati.  
La seconda parte del lavoro presentato si è focalizzata sullo sviluppo di un approccio 
immunoterapeutico per il cancro al pancreas. Il potenziale immunogenico delle cellule 
tumorali necrotiche sta ricevendo grande attenzione, in considerazione sia della sua 
importanza nell‟aumento delle cellule T citotossiche specifiche per l‟immunoterapia 
tumorale, sia della sua importanza come migliore fonte di antigeni tumorali (TAA) per le 
cellule dendritiche (Lake et al., 2005; Nowak et al., 2006). Le cellule dendritiche sono 
cellule in grado di presentare efficacemente un antigene a linfociti T e, come mostrato di 
recente, possono essere attivate da molecole DAMPs come l‟HMGB-1 e l‟HSP-70, che 
sono altamente espresse sulla superficie di cellule tumorali necrotizzate soprattutto dopo 
trattamento ipertermico e che inducono l‟immunità antitumorale (Shi et al., 2006; Bianchi 
et al., 2007; Chen et al., 2009). La presentazione antigenica mediante cellule dendritiche è 
essenziale per ottenere risposte effettive delle cellule antitumorali T in pazienti malati di 
cancro, ma essa dipende dall‟origine, dallo stato di maturazione e dal milieu citochinico. 
Per questo motivo abbiamo focalizzato la nostra attenzione sull‟attivazione di una risposta 
immunitaria che protegga dal tumore, usando PaCa-44, PT-45, PANC-1 e PANC-2, tutte 
linee cellulari umane di tumore al pancreas. 
Abbiamo sviluppato una strategia immunoterapeutica basata su cellule dendritiche umane 
ottenute dal sangue di donatori sani, caricate con cellule tumorali necrotizzate dopo 
incubazione a 56°C o esposizione agli UVC.  
Questo approccio immunoterapeutico pare promettente, soprattutto qualora si ricorra 
all‟esposizione agli UVC come trattamento per necrotizzare il tumore. I trattamenti hanno 
indotto l‟apoptosi seguita da necrosi secondaria delle cellule tumorali e il rilascio nel 
surnatante di livelli di DAMPs più alti di quelli riscontrati senza trattamenti. 
 Riassunto 
 
9 
 
Le DAMPs sono responsabili della stimolazione delle cellule dendritiche e, 
conseguentemente, dell‟aumento del potere immunogenico delle cellule tumorali 
necrotiche, come mostrato dai più alti livelli dei marcatori della maturazione CD80, CD83 
e MHC-II espressi dalle cellule dendritiche in presenza delle cellule tumorali necrotiche. 
La necrosi secondaria ha avuto come risultato anche un miglioramento dell‟efficienza di 
fagocitosi di materiale necrotico da parte delle cellule dendritiche per tutte e quattro le 
linee cellulari utilizzate. La specifica risposta immunitaria ottenuta quando le cellule T di 
un donatore sono state aggiunte a cellule dendritiche autologhe attivate in base ai protocolli 
da noi standardizzati, è cambiata da una linea cellulare all‟altra e a seconda del donatore 
utilizzato. Una risposta immunitaria specifica è stata ottenuta in vitro solo per le linee 
cellulari PaCa-44 e PT-45, e non contro le linee cellulari PANC-1 e PANC-2. Questi 
risultati sono stati confermati anche in vivo in un protocollo di immunoterapia curativa 
usando solo le cellule tumorali PaCa-44 e PT-45, nonostante il numero esiguo di linfociti-T 
iniettati per singolo animale ed il numero di animali a disposizione per ciascun gruppo 
sperimentale siano stati e restino tuttora un punto cruciale nello sviluppo del modello 
preclinico. 
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I. Introduction 
 
Chapter 1: Pancreatic cancer 
 
1.1.1. Pancreas anatomy and physiology 
 
Pancreas is a retroperitoneal organ of endodermal derivation involved in glucose 
homeostasis and protein and carbohydrate digestion.  Pancreas is located deep in the 
abdomen and it has a close anatomical relationship with the duodenum and the common 
bile duct. Anatomically, pancreas can be divided into three parts: head (caput), body 
(corpus) and tail (cauda). Functionally, it is a composite exocrine-endocrine gland. 
The major components of the pancreatic parenchyma are (Figure1): 
1. Acinar and duct cells (80% of the tissue mass of the organ), that are organized in 
a branching network. The acinar cells are functional units along the duct 
network and they synthetize and secrete zymogens into the ductal lumen in 
response to cues from the stomach and duodenum (Hezel A.F et al., 2006). 
Close to ducts, there are the central-acinar cells; the duct system begins within 
the acini themselves (Grapin-Botton A., 2005) . The interlobular ducts are the 
largest ones and they drain directly into the duct of  Wirsung, the main 
pancreatic duct. Taken togheter, they represent the exocrine portion of pancreas. 
 
2. Four specialized endocrine cell types (α, β, δ and PP), gathered together into 
clusters called islets of Langherhans (about 2% of pancreas volume). They are 
involved in the regulation of metabolism and glucose homeostasis through the 
secretion of hormones into the blood-stream, such as insulin (from β cells), 
glucagon (from α cells), somatostatin (from δ cells) and pancreatic polypeptide 
(from PP cells). They represent the endocrine portion of the gland. 
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Figure 1 Pancreas. Overall anatomy of pancreas and components of pancreatic parenchyma: islets of 
Langherhans, acini and ducts. © G. Andersson, 2010 
 
 
Mirroring the physiologic and cellular diversity of pancreas gives an idea of the 
spectrum of distinct pancreatic malignancies, that possess histological and molecular 
features recalling the characteristics of the normal cellular costituents (Hezel A.F et al., 
2006). 
 
 
1.1.2 Pancreatic cancer: classification 
 
“Pancreatic cancer” is a broad term to describe as many as 20 different types of tumor 
that occur in pancreas. The phenotypic classification of pancreatic neoplasms is based 
on their cellular lineage of origin (acinar, ductal and endocrine phenotype). Based on 
this classification, we can distinguish exocrine and endocrine pancreatic tumors. 
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Exocrine tumors represent the majority of pancreatic neoplasms (more than 90%), and 
can be ductal or acinar. 
 
Exocrine tumors: ductal tumors 
Pancreatic Ductal AdenoCarcinoma (PDAC) is the most common pancreatic cancer and 
accounts for >85% of cases (Warshaw and Fernandez del Castillo 1992; Li D. et al., 
2003; Hezel A.F et al., 2006). Microscopically, they are well differentiated, showing 
tubular structures, cystic formations and papillar structures. Despite the well 
differentiated appearance, the ductal adenocarcinoma is characterized by a highly 
aggressive, rapid and infiltrative growth pattern. A quite unique feature is the extensive 
stroma, referred to as the desmoplastic reaction (most of the tumor volume), that 
surrounds and infiltrates clusters of cancer cells. A ductal adenocarcinoma often 
develops through different premalignant states called Pancreatic Intraepithelial 
Neoplasia (PanIN), that will be described later in this chapter. Beside the PanINs, there 
are cystic lesions with premalignant potential, especially mucinous cysts. 
Less common tumors with a ductal phenotype are the variants of ductal 
adenocarcinoma, intraductal papillary mucinous neoplasm (IPMNs, including colloid 
carcinoma), mucinous cystic neoplasm (MCNs), medullary carcinoma and other rare 
tumors (Kloppel G. et al., 2004). They show malignant potential and up to one third has 
an associated invasive cancer (Tanaka et al., 2006). The cystic lesions frequently are 
associated with clinical manifestations, such as abdominal pain, nausea and jaundice, 
whereas PanINs are often asymptomatic. 
IPMNs are constituted of proliferative intraductal neoplastic cells with papillary 
characteristics that produce mucin. IPMNs derived from the main duct are more prone 
to harbor invasive cell components compared to IPMNs found in the branch ducts 
(Tanaka et al., 2006). 
MCNs are most common in perimenopausal women and they are characterized by 
thick-walled multilobular cysts, often without comunication with the ductal part 
(Thompson et al., 1999). 
Therefore, the ductal adenocarcinomas are the most common types of pancreas cancer 
and they have the most clinical relevance; for these reasons, the expression “pancreatic 
cancer” in common language is often used when referring to the ductal 
adenocarcinomas. 
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Exocrine tumors: acinar tumors 
Less than 1% of all pancreatic cancers derive from the acinar cell lineage. Acinar cell 
carcinoma (ACC) lacks the desmoplastic stroma found in ductal adenocarcinoma and is 
often large in volume at the time of diagnosis. Most of the ACCs produce digestive 
enzymes such as trypsin and lipase (Klimstra et al., 1992). In some cases, the enzymes 
secreted cause fat necrosis due to lipase hypersecretion. The median survival of ACCs 
is approximately 19 months, which makes acinar cell carcinoma more aggressive than 
endocrine tumors (PENs) but less aggressive if compared to ductal adenocarcinomas 
(Holen et al., 2002). 
 
Endocrine tumors 
Endocrine tumors are only about 1% of all cases and they affect the hormone-producing 
cells of pancreas.  
The most common endocrine tumors are the Pancreatic Endocrine Neoplasms (PENs) 
(Heitz et al., 1982). PENs are low-grade malignancies and arise from the islets of 
Langherans; only 50% of PENs really secrete hormones and they are called “functional” 
(Kloppel & Heitz, 1988). 
The functional PENs are named differently, depending on the hormone secreted (i.e. 
insulinoma, glucagonoma etc.) and the result is a dramatic increase   in the amounts of 
hormones produced with a variety of symptoms: for istance, patients with  insulinoma 
often show extreme hypoglycemia. 
 
 
1.1.3 Epidemiology and risk factors of pancreatic cancer 
 
Pancreatic cancer is one of the most lethal human cancers and a major unsolved health 
problem. PDAC ranks 8
th
 in a worldwide ranking of cancer deaths (Lowenfels AB et al., 
2006); but it ranks 13
th
 respect to incidence, as it is considered a relatively rare tumor. 
PDAC is characteristically a tumor of elderly individuals: 80% of cases occurs in 
patients between 60 and 80 years of age, while patients below 40 years are rare (Luttges 
J et al., 2004). The disease is also more prevalent in males than in females (Raimondi S. 
et al., 2009). 
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Pancreatic cancer patients have poor 5-year survival rate (for only 5%) and the median 
survival is less than 6 months. One of the main problems with pancreatic cancer is late 
onset, with hindering of clinical research. Jaundice, resulting from obstruction of biliary 
ducts, is often the first symptom, although it generally appears after the tumor has 
metastasized. Many other symptoms are non-specific as abdominal pain, nausea, 
vomiting, itchy skin and loss of weight and appetite (Lillemoe KD et al., 2000; 
Sakorafas et al., 2000). Thus, diagnosis is difficult and close to 100% of patients with 
pancreatic cancer already show metastasis at the time of diagnosis. 
The incidence rate of pancreatic cancer differs among countries suggesting that 
environmental or lifestyle risk factors may be part of etiology, even if only a few factors 
are still known. Early epidemiologic studies suggest that carcinogens from tobacco or 
other environmental sources might enter the bile and reflux through the pancreatic duct, 
causing pancreatic cancer (Wynder EL et al., 1973). This hypothesis could explain the 
excess of incidence of pancreatic neoplasms in the head of pancreas. 
Current data confirm three types of risk factors: cigarette smoking, diabetes and chronic 
pancreatitis (Li D et al., 2004). 
a) Smoking increased of 2-3 times the risk of pancreatic cancer in current smokers 
compared to people who have never smoked (de Braud F et al., 2004). Exposure to 
environmental smoking (passive smoking) causes a non-significant increase of the risk. 
The effect of smoking is related to the mutagens present in the metabolites of tobacco 
(Lowenfels et al., 2006). 
b) Type II diabetes and pancreatic cancer also have an interesting but unclear 
relationship (Huxley et al., 2005). Often, patients with pancreatic cancer develop 
diabetes and patients with diabetes have an increased risk of developing cancer. This 
indicates that there are etiological associations to dietary factors and glucose 
metabolism. 
c) Pancreatitis is linked with pancreatic cancer (Lowenfels et al., 1993; Bansal P et al., 
1995). Even though the causal relationship between pancreatitis and pancreatic 
neoplasms is not well understood, the most likely hypothesis is that a constant 
inflammatory reaction in pancreas leads to transformative events in pancreatic cells. 
The most common cause of pancreatitis is alcohol consumption (Genkinger et al., 2009) 
but there could also be genetic risk factors: patients with hereditary pancreatitis 
experience show a 53-fold increased incidence of pancreatic cancer (Bardeesy N. et al., 
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2002). The link between chronic pancreatitis and pancreatic cancer has not been fully 
investigated. 
 
 
1.1.4 Malignant transformation and genetic alterations 
 
Pancreatic intraepithelial neoplasms (PanINs) are precursors of invasive pancreatic 
cancer that develops from ductal epithelium, and they accumulate histological and 
genetic abnormalities in their progression towards an invasive management. 
The PanINs nomenclature has been standardized by Hruban et al. in 2001: they are 
divided into different stages, from PanIN-1A to PanIN-3 (Figure 2A). 
The normal duct has a low-columnar epithelium. At the PanIN-1A stage, the epithelium 
becomes taller, with still basally located non-atypical nuclei, and it shows a papillary or 
pseudo-stratified structure in PanIN-1B. In PanIN-2, cells lose their polarity and lesions 
manifest architecturally as flat or papillary lesions with higher degree of nuclear atypia. 
In stage PanIN-3 (also called “carcinoma in situ”), clusters of epithelial cells are 
budding off and can be found in the lumen. These cells are characterized by nuclear 
atypia, prominent nucleoli and mitotic activity (Baumgard M et al., 2005; Takaori K et 
al., 2004; Hruban RH et al., 2000). 
Tissue microarrays have been used to identify genetic alterations occurring in the 
different PanIN stages (Maitra et al., 2003). It has been shown that molecular alterations 
in the PanINs are not random but, on the contrary, they follow a specific sequence 
during PanIN development, which is fundamental for the malignant transformation. The 
genetic basis in pancreatic cancer is extremely complex and heterogeneous (Jones et al., 
2008). 
The molecular changes can be stratified into groups of early, intermediate and late 
alterations, summarized in Figure 2B. 
Interestingly, the activation of K-ras mutations and the telomere lenght shortening are 
nearly ubiquitous and occur early in the transformation process, indicating the 
importance of these molecules in the pathogenesis of pancreatic cancer (Bardeesy & 
DePinho, 2002).K-ras mutations are the first molecular abnormality detectable in PanIN 
and they can be considered a “signature” of pancreatic cancer. Telomerase activity is 
significantly higher in invasive lesions compared to normal adjacent structures. 
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Nevertheless, it is peculiar that this high activity is preceded by shortage of telomeres, 
that have been documented in all types of pre-invasive lesions (Heek NT et al., 2002). 
The second step include p16, p53, DPC4 and BRCA2 genes inactivation. 
Furthermore, recent studies indicate that cell damage and inflammation, which occur 
during acute or chronic pancreatitis, result in an acinar-to ductal metaplasia (acinar cells 
during tissue regeneration show duct-like morphology). In the normal pancreas, this 
metaplasia is transient but, if K-ras is mutated, the acinar-to-ductal metaplasia can 
become persistent and develop PanINs lesions (Morrison et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A: Morphological appearance and genetic alterations in different PanIN-stages (Maitra et al., 
2003). B: Molecular changes stratified as early, intermediate or late. 
 
 
1.1.5 Biological models for Pancreatic Cancer 
 
Two model systems for studying pancreatic adenocarcinoma have been developed: in 
vivo models, that employ animal models, and in vitro models, that use cell lines and 
pathological specimens. Each of these models has advantages and disadvantages. 
Animal models offer the possibility to study both temporal and spatial events, but the 
biological properties of pancreatic tumors in these models are different from humans 
and so interpretation of these findings need to be viewed cautiously.  
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On the other hand, tumor cell lines are useful for evaluating responses of tumors to 
drugs in preclinical studies and harbour all the genetic damages that lead to 
transformation and metastasis. The disadvantage is that it is not possible to determine 
the temporal order at which such defects have occurred. 
Tumor specimens are useful to understand premalignant lesions and spatial arrangement 
of tumors that occur in tumor progression, but the events that precede and follow the 
time point at which the specimen was taken, cannot be determined. 
So it is necessary to use all these systems to better understand pancreatic 
cancerogenesis. 
 
Mouse models: xenograft 
Since their introduction in 1966 (Flanagan S.P., 1966), nude mice have gained 
popularity as a model to study human tumor biology because they are able to host 
cancer cells. They are also used to examine the effects of therapeutic drugs or radiation 
particularly in cancers difficult to manage, such as pancreatic cancer. 
Implantation of tumor cells in the subcutaneous tissue has limited clinical value since 
spontaneous metastasis in parenchymatous organs are rarely observed. Subcutaneous 
tumors in donor animals never metastasized and resembled encapsulated benign tumors 
rather than infiltrative malignancies, even if derived from undifferentiated or poorly 
differentiated cell lines. 
Orthotopic models, in which tumor cells are directly injected in murine pancreas, are 
considered more appropriate to mimic the clinical situation, because they allow the 
growth of cellular clones with metastatic potential. However, this technique is strongly 
operator-dependent and frequently there is a simultaneous metastatic spread of cancer 
cells into the intra-abdominal organs during injection procedure. 
The orthotopic implantation of fragments has been proposed as a superior technique 
compared to cell injection (Hotz HG et al., 2003). Dislocation of tumor fragments from 
implantation site was not observed, but the metastatic potential is only about 50 % 
versus the 100% observed in human disease. 
 
Mouse models: genetically engineered mice (GEM) 
Genetically engineered mice (GEM) have provided a successful in vivo system to study 
the biological impact of oncogenic mutations (Weiss WA, van Dyke et al, 2002). GEM 
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have the potential to identify early markers of disease and provide better preclinical 
models for therapeutic initiatives. 
Human PDACs show mutational activation of K-ras gene and inactivation of Ink4a, Arf 
and p53 tumor suppressor genes. 
In the Kras Ink4a/Arf engineered model, all PDACs retain p53 function, indicating that 
loss of p53 is not an obligatory step for tumor progression. A notable feature of these 
models is the maintenance of the wild-type SMAD4 expression in all tumors. However, 
these data suffer of some important differences in reciprocal interactions of Arf, p53 
and Ink4a between mice and humans (Aguirre AJ et al., 2003; Rangarajan et al., 2004). 
Human PDACs are characterized by widespread chromosomal instability. Its origin 
include a number of defects involving the mitotic spindle apparatus, various cell cycle 
checkpoint pathway, telomeres dysfunction, increased ROS and defects in DNA repair 
(Hezel AF et al., 2006). Genomic analysis using CGH-arrays and spectral karyotyping 
(SKY) have found that all the evaluated PDAC models show evidence of a global 
genomic alteration, suggesting that at least some of the mechanisms driving genomic 
instability are active in these mouse models. Anyway, the absolute number of 
chromosomal structural aberrations in the current collection of GEM appears less than 
that observed in humans. 
So, even if mouse model are helpful, it remains to be determined whether there are 
cross-species differences in the oncogenic pathways leading to development of PDAC. 
 
In vitro models 
The establishment of a large bank of pancreatic cancer cell lines from a wide panel of 
human cancer specimens may reflect the diversity of tumor phenotypes and could 
provide adequate models for studying pancreatic cancer disease heterogeneity. 
Recently, cancer studies have acknowledged the active roles that tumor stroma can play 
in carcinogenesis, focusing on the abnormal communication between tumor cells and 
their microenvironment. 
The intense stromal interaction between cancer cells and orthotopic tumor-derived 
fibroblasts is a predominant characteristic of pancreatic cancer even if it is not well 
understood. So, co-culture experiments with or without a transwell chamber can be 
helpful to clarify these interactions with microenvironment. 
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However, these in vitro experiments do not consider the role of the extracellular matrix. 
Recently, experimental models have been developed to provide the in vitro stroma 
microenvironment for cellular interaction: collagen gel-based co-culture models 
represent a valid model to study cellular interactions (Che Z.M. et al., 2006). 
 
 
1.1.6 Treatments of Pancreatic Cancer 
 
Treatment strategies for pancreatic cancer have evolved in the last years and new drugs 
have been introduced, but unfortunately there is no curative treatment and palliative 
care is the most likely outcome. Even a small benefit from a new treatment is important 
for pancreatic cancer patients. 
 
Early disease 
Tumor at stage I or II can be candidate for surgery, whereas stage III and IV tumors are 
considered unresectable.  
For localized tumors, surgery is the treatment of choice, but only 20% of the patients 
have a resectable disease at the time of diagnosis (Bilimoria et al. 2007). Depending on 
the localization, different surgical strategies are used: the cephalic pancreato-
duodenectomy, called Whipple procedure, is preferred for tumors of the head of 
pancreas, distal pancreatectomy in the cauda and total pancreatectomy for large cystic 
lesions. Only in total pancreatectomy the whole pancreas is removed and both hormones 
and digestive enzymes must be substituted lifelong. 
As a complement to surgery, adjuvant chemotherapy, given post-surgery, improves the 
progression-free survival (Neoptolemos et al., 2004; Regine et al., 2008), but the overall 
survival is only marginally affected (Oettle et al., 2007). 
 
Locally advanced and systemic disease 
For the rest of the patients with locally advanced or systemic disease, the treatment of 
choice is palliative chemotherapy. However, the active treatment is beneficial because 
the survival in patients with locally advanced disease is improved with chemotherapy 
(Sultana et al., 2007). 
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Gemcitabine (GEM) is a nucleoside (cytidine) analogue that incorporates into the DNA 
and blocks DNA replication; 5-fluorouracil (5-FU) is an inhibitor of the thymidylate 
synthetase. These are the two chemotherapeutic agents most evaluated in pancreatic 
cancer. Randomized trials have shown gemcitabine to be more effective than 
fluorouracil when administered intravenously (Burris et al., 1997), making gemcitabine 
the gold standard drug for the last decade. 
Even though pancreatic cancers show an active neo-angiogenesis and an over-
expression of Vascular Endothelial Growth Factor (VEGF), anti-angiogenetic 
approaches have been tried with MMP-inhibitors and anti-VEGF agents, but they failed 
(Saif, 2006). A large phase III trial has been recently published comparing gemcitabine 
with a combination of gemcitabine and bevacizumab, a monoclonal antibody that 
targets and blocks VEGF. This trial did not improve patients survival (Kindler H.L et 
al., 2005; Kindler H.L et al., 2010).  
Also endostatin, an anti-angiogenic agent derived from type XVIII collagen, has been 
tested: interestingly, association of endostatin with gemcitabine had better effects than 
gemcitabine or endostatin in monotherapy in an animal xenograft model of human 
pancreatic cancer (Wang et al., 2010),but no results from clinical trials are available.  
Many studies have been performed attempting to inhibit the cyclooxygenase 2 (Cox-2) 
in pancreatic cancer. Cyclooxygenase 2 (Cox-2) is an enzyme that produces 
prostaglandins that can lead to inflammatory promotion of cellular transformation. Its 
expression in pancreatic cancer has been correlated with a poorer prognosis (Juuti et al., 
2006). 
 
 
1.1.7 Survival 
 
The overall median survival in pancreatic cancer is between 4 and 5 months (Bilimoria 
et al., 2007), and the major causes of death are peritoneal dissemination or liver 
metastasis (Saif, 2006). Bilimoria et al have studied the survival in pancreatic cancer in 
relation to stage, and compared resected to non resected tumors in a large patient 
population with over 121.000 pancreatic cancer cases. Their results show that resection 
of a tumor at a low stage improves dramatically the survival, but the gain in survival 
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diminishes at higher stages. Patients with a low stage (small tumor with no signs of 
disseminated disease) only show a median survival of 24,1 months after surgery. 
Long-term survival only occurs in 10-20% of the patients that undergo surgery with 
curative intent (without chemotherapy) (Yeo et al., 1995; Goldstein et al., 2004). 
Pancreatic cancer produces metastasis early and we do not have the instruments to 
correctly classify the disease today. During the past decades, the 5-year survival rate has 
only improved marginally, and today it is about 5% in the Nordic countries (Storm et 
al., 2007), in Europe (Sant et al., 2009) and in the United States (Bilimoria et al., 2007; 
Jemal et al., 2008) This makes pancreatic cancer the tumor type with the lowest long-
term survival rate among all the most common malignancies. Thus new therapies are 
needed and immunotherapy could be an option. 
 
 
Chapter 2: Features of immune system 
 
1.2.1 Innate and adaptive immunity 
 
The immune system has evolved numerous strategies to counteract pathogens that we 
encounter throughout our lifetimes. The immune system can be divided into innate and 
adaptive.  
The innate (natural) response is non-specific and it is the first-line of defense against 
different pathogens. Innate immunity is a multi-pronged attack by specialized cells and 
proteins, including acute phase proteins, the complement system, inflammatory 
mediators (such as IFNs) and antimicrobial peptide as defensins. Phagocytic cells 
(neutrophils and macrophages) engulf and then kill microorganisms and foreign 
molecules, whilst natural killer cells (NKs) patrol the cell surface of cells they 
encounter for “self” molecules of the major histocompatibility complex (MHC) and kill 
any cells lacking these molecules (Lyunggren et al., 1990; Smyth et al., 2002). 
The adaptive (acquired) immune response, which is initially slower, eventually mounts 
a specific response that clears the infection and culminates in immunological memory. 
The main cells of the adaptive immune response are B and t lymphocytes. Adaptive 
immunity is elicited when T and B lymphocytes specifically recognize the antigen and 
become activated. Activation of T lymphocytes occurs via the T cell receptor (TCR)-
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mediated recognition of an antigenic peptide presented by MHC molecules expressed 
on the surface of an antigen presenting cell (APC), which collect antigens from its 
surroundings, processes into peptides, assembles the peptides to MHC molecules and 
finally exposes the MHC-antigenic peptide complexes on cell surface.. There are two 
major types of MHC molecules, named MHC class I (MHC-I) and MHC class II 
(MHC-II) molecules, playing different roles in antigen presentation to T cells.  
B lymphocytes also bind antigens utilizing an antigen-specific receptor called the B cell 
receptor (BCR), a cell-surface immunoglobulin molecule. After the initial lymphocytes 
activation, adaptive immunity leads to a memory response, where secondary exposure 
to the same antigen produces a faster and stronger response. The adaptive immune 
system can be divided into a humoral and a cell-mediated arm. Humoral adaptive 
immunity consists of antibody-producing B cells and cell-mediated adaptive immunity 
is mainly mediated by CD4
+
 T-helper cells (Th) and CD8
+
 cytotoxic T cells (CTLs). 
 
 
1.2.2 T lymphocytes and T-cell receptor (TCR) 
 
The TCR is a heterodimer consisting of two transmembrane polypeptide chains, 
designated α and β, covalently linked to each other by disulfide bonds. Similarly to 
immunoglobulin heavy and light chains, each α- and β-chain consists of one Ig-like N-
terminal variable domain (V), one Ig-like constant domain (C), a hydrophobic 
transmembrane region and a short cytoplasmic region. The V regions of α- and β-chains 
contain short stretches of amino acids where the variability between different TCRs is 
concentrated, and these form the hypervariable or Complementary-Determining 
Regions (CDRs). Three CDRs of the α-chain are juxtaposed to three similar regions of 
β-chain to form the part of the TCR that specifically recognizes peptide-MHC 
complexes. 
The TCR complex is not produced in a secreted form and it does not perform effector 
functions on its own, but initiates signals that activate the effector functions of T cells. 
Peptide-MHC complexes recognition relies on the CDRs loops of both TCR α- and β-
chains. The affinity of TCR for peptide-MHC complexes is low and it is the likely 
reason for the need of accessory molecules to stabilize T cell adhesion to APCs, thus 
allowing biological responses to be initiated. 
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The TCR α- and β-chains display very short intracytoplasmic tails, unable to transduce 
signals inside the cell, and so they are non-covalently associated to the CD3 complex 
and to δ proteins; when the TCR recognizes antigen, these associated proteins transduce 
the signals that lead to T cell activation (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: schematic representation of a TCR complex with the  and  chains of the MHC-interacting 
receptor associated to the , ,  chains (CD3) and to δ proteins (Abbas AK et al. 2010).  
 
 
In addition to the TCR, T cells express other integral membrane proteins that play 
crucial roles in the responses of these cells: the accessory molecules. 
These molecules bind other molecules (ligands) that are present on the surfaces of other 
cells and in the extracellular matrix; they are non-polymorphic and invariant; they 
transduce biochemical signals to the interior of the T cell that are important in 
regulating functional responses; they increase the strength of adhesion between T cells 
and APCs and they are important for the homing and retention of T cells to tissues.  
 
 The co-receptors CD4 and CD8, once bound to the non-polymorphic regions of 
MHC molecules, transduce signals that, together with signals delivered by the 
TCR complex, initiate T cell activation. Depending on the type of TCR-
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associated co-receptor CD4 or CD8, T lymphocytes can be divided into two 
main groups: T CD4
+
 and T CD8
+
. The co-receptor found on cell surface can 
also be considered a functional marker: CD4 binds to the 2 domain and to non-
polymorphic portions of the 1 domain of the MHC-II  chain, and CD4+ T 
cells interact with cells expressing MHC-II, i.e. mainly professional APCs, 
presenting antigens phagocytosed from the external environment. CD8 binds to 
the 3 domain of the MHC-I  chain, and CD8+ T cells interact with cells 
expressing MHC-I, i.e. professional APCs but also any type of nucleated cell, 
presenting cytosolic antigens. 
 
 CD40L (CD154) is one of the most potent costimulatory molecule and interacts 
with its cognate receptor, CD40, on the APCs. It is responsible for a reciprocal 
activation, because it is able to upregulate costimulatory and adhesion molecules 
on the APCs. 
 
  CD28 is a membrane protein that transduces signals that function together with 
signals delivered by TCR complex to activate T cells and recognizes B7 
molecules on APCs. 
 
 A second receptor for B7 molecules is CTLA-4,  expressed on recently activated 
CD4
+
 and CD8
+
 T cells. Its function is to inhibit T cell activation by 
counteracting signals delivered by CD28. 
 
T cell proliferation in response to antigen recognition is mediated primarily by an 
autocrine growth pathway, in which the responding T cells secrete their own growth-
promoting cytokines (particularly IL-2) and also express cell surface receptors for these 
cytokines. Some of the progeny of antigen-stimulated T cells develop into long-lived, 
functionally quiescent memory cells, which are responsible for enhanced and 
accelerated secondary immune responses on subsequent exposures to the same antigen. 
The main cytokine produced by T cells is IL-2, that functions as a growth factor for the 
T cells. Under different activation conditions, naïve T cells that are stimulated by 
antigens may differentiate into subsets that secrete distinct sets of cytokines and 
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perform different effector functions (Lyunggren et al., 1990; Smyth et al., 2002) (see 
1.2.5). 
 
 
1.2.3 Antigen presenting cells: dendritic cells (DCs) 
 
Dendritic cells (DCs) are professional antigen presenting cells (APCs) of hemopoietic 
origin with potent effects on primary T cell differentiation and activation and thus are of 
central relevance to immune responses and vaccine development (Thery et al., 2001; 
Banchereau et al., 2000). DCs are present in lymphoid organs, in the epithelia of the 
skin,gastrointestinal and respiratory tracts (the main portals through which microbes can 
enter), and in most parenchymal organs.  
Although many cells can function as APCs such as macrophages, B cells and some 
epithelial cells, DCs are by far the most potent APCs given their unique ability to 
stimulate naive T cells (Guermonprez et al., 2002). 
DCs form a physical link between the periphery and the secondary lymphoid organs, 
acting as sentinels for “dangerous” antigens in the peripheral tissues and then migrating 
to secondary lymphoid organs, in the areas where naive T cells are located, to transmit 
information about the nature of the pathogen and the infected tissues.  
At the immature stage, DCs exhibit potent endocytic activity and express various 
receptors mediating endocytosis of particulate antigens, debris from pathogens and dead 
cells.  
They take up antigen via non-specific receptors for Pathogens Associated Molecular 
Patterns (PAMPs). Internalized antigens are then processed into peptides in specific 
vescicular compartments and associated to MHC-II molecules. More often in DCs than 
in B cells or macrophages, portions of internalized antigen may also exit the endocytic 
vesicles and enter the cytosolic pathway of antigen processing and presentation, to be 
presented in association with MHC-I molecules (cross-priming). 
During the process of maturation, mostly associated with their migration from the 
periphery to lymphoid organs, DCs shift from an antigen-capturing mode to a T cells-
sensitizing mode. The maturation process is induced by microbial products (LPS, CpG 
oligonucleotides), inflammatory chemokines (TNF-, IL-1), T cells (through 
CD40/CD40L interaction) and stress (necrosis, transplantation) (Smyth et al., 2001). 
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DCs maturation induces a down-regulation of antigen uptake and processing capacity 
and an up-regulation of immunostimulatory properties like expression of B7-1 and B7-2 
co-stimulatory molecules and MHC-II molecules. 
Two types of DCs precursors have been identified in human peripheral blood: 
monocytes, which differentiate into immature myeloid DCs (MDCs), upon exposure to 
GM-CSF and to IL-4, and plasmacytoid cells, that display features of the lymphoid 
lineage and require IL-3 for their development into plasmacytoid DCs (PDCs) (Rissoan 
et al., 1999; Liu et al., 2001). 
Upon activation, mature MDCs produce large amounts of IL-12 and preferentially 
induce naive CD4
+
 T cells to differentiate into Th1 cells, whereas mature PDCs produce 
low level of IL-12 and induce the development of Th2 cells (Moser et al., 2000; Belz et 
al., 2002) or immunosuppressive T cells (Moseman et al., 2004). 
So, the functional properties of DCs are affected by their state of maturation when 
encountering T cells. For example, repetitive stimulation of alloreactive T cells with 
mature CD83
+
 human monocyte-derived DCs induces predominantly Th1 responses.  
By contrast, repetitive stimulation with immature CD83
-
 DCs favors the emergence of 
non-proliferating, IL-10 producing T cells ( Jin et al., 2004 ), the human counterpart of a 
recently described population of immunoregolatory T cells involved in maintaining 
peripheral tolerance ( Jonuleit et al., 2000; Fontenot et al., 2004; Sakaguchi 2004 ).  
 
 
1.2.4 Antigen presentation pathway 
 
MHC molecules reveal which proteins are produced by the cell in a particular  time 
point and which proteins are taken up from its surrounding milieu. In this way, they 
provide a means for T cells to inspect this antigenic repertoire and detect peptides 
derived from intra- or extra-cellular pathogens. 
Peptides originating from endogenous proteins are loaded onto MHC-I molecules and 
are displayed to CD8
+
 T cells, while exogenous antigens are primarily loaded onto 
MHC-II molecules to be presented to CD4
+
 T cells. 
The MHC-I molecule, consisting of 2 polypeptide chains, namely constant β2 
microglobulin and variable α chain, is present on almost every nucleated cell. Upon 
ubiquitination, endogenous proteins are delivered to the proteasome in the cytosol, 
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where they are degraded into peptides. The peptides are then translocated to the 
endoplasmic reticulum (ER) via a molecular complex named “transporter associated 
with antigen processing (TAP)” and eventually bound to MHC-I within the peptide-
binding cleft (York et al., 1996). MHC-I-bound peptides are tipically 8-12 amino acids 
long (Tong et al., 2004).  
Finally, the MHC-I-loaded molecule travels via the Golgi to the cell surface where the 
peptide/MHC complex is displayed to CD8
+
 T cells. 
Interferon- (IFN-) can induce upregulation of the three proteasomal subunits LMP2, 
LMP7 and MECL1 (Akiyama et al., 1994). This so-called immunoproteasome is 
distinct from the standard proteasome: it produces different sets of peptides, due to 
altered cleavage patterns. While immature DCs express both the immunoproteasome 
and standard proteasome in equal parts, mature DCs express only immunoproteasome 
(Macagno et al., 1999). 
At first glance, it seems that the immunoproteasome might be more efficient in antigen 
presentation than the standard proteasome, since its cleavage patterns yield peptides 
with the anchor residues that bind to MHC-I most efficiently. Nevertheless, some 
epitopes cannot be processed by the immunoproteasome and this means that T cells 
directed against these epitopes will not be activated by mature DCs and therefore 
remain quiescent. For tumor antigens, the immunoproteasome is more efficient, while 
the standard proteasome is more effective in processing other epitopes. This has strong 
implications for immunotherapy, both for cancer and infectious disease, regarding the 
optimal immunization protocol for a particular antigen (Van den Eynde et al., 2001; 
Morel et al., 2000). 
 
The MHC-II molecule, which consists of an  and  chain, both polymorphic, is present 
on APCs such as DCs, macrophages and B cells (Wang et al., 2001). Exogenous 
antigens can be taken up via macropinocytosis (non-specific uptake of extracellular 
fluid), phagocytosis (receptor-mediated attachment and engulfment) or receptor-
mediated endocytosis (binding to clathrin-coated pits) (Brode et al., 2004). After uptake 
by one of these processes, exogenous proteins are transported by early endosomes, that 
eventually become late endosomes. In the late endosome, the process of acidification  
activates proteases to generate peptides. 
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MHC II molecules are produced in the ER, but subsequently enter vescicles that fuse 
with late endosomes, so the MHC molecules can bind peptide (Wang et al., 2001). 
MHC II bound peptides are generally 9-25 amino acids in length, and even longer 
(Tong et al., 2004). The antigen presentation pathways are represented in Figure 4. 
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Figure 4: MHC-I and –II molecules and antigen presentation pathways. A) Schematic representation of an 
MHC-I and -II molecules. B) Exogenous (for MHC-II) and  endogenous (for MHC-I) antigen presentation 
pathways. (Abbas AK et al. 2010).  
 
 
A) 
B) 
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1.2.5 The immunological synapse 
 
Immature DCs are sentinels of the immune system that travel through the body 
sampling the antigenic milieu, and therefore they have an enhanced capacity to take up 
antigens. 
Upon maturation, DCs upregulate homing receptors (e.g. CCR7) and migrate to 
draining lymph nodes (Allavena et al., 2000). At this point, their enhanced ability to 
take up antigens is replaced by enhanced capabilities to provide T cell costimulation. 
In lymphoid tissues, naive T cells travel through surveying other cells in search of an 
antigen they are specific for. According to the two signals hypothesis (Lafferty et al., 
1975), a T cell is efficiently activated when it recognizes its specific MHC/peptide 
complex via its TCR. This primary signal is followed by a second signal, delivered 
when costimulatory receptors on the APC are bound to their cognate ligands on the T 
cell. Without this costimulatory signal, the T cell enters a state of anergy (Jenkins et al., 
1987). 
There are two prominent families of costimulatory molecules which provide the second 
signal in T cell activation: 1) members of the immunoglobulin superfamily, such as 
CD28 and ICOS; 2) members of the TNF superfamily, such as CD40L (CD154) and 
TNF-related activation-induced cytokine (TRANCE). One of the most potent 
costimulatory molecules is CD40L, which interacts with its receptor, CD40, on the 
APC. This costimulatory signal not only activate the T cell, but reciprocal activation 
occurs since the CD40-CD40L interaction upregulates costimulatory and adhesion 
molecules on the APC, such as CD80, CD83, CD86, ICAM I and LFA3 (van Kooten et 
al., 1997; Cella et al., 1996). 
There are also other members of these two families which inhibit T cell responses. One 
inhibitory molecule of T cells is the cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4), that binds with high affinity CD80 and CD86 ligands on APC (as CD28). 
These interactions are represented in Figure 5. 
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Figure 5. The immunological synapse. For optimal T cell activation, signal 1 (TCR-MHC/peptide) and 
signal 2 (costimulation) must be provided. Signals from molecules such as CTLA-4 inhibit activation. 
 
 
1.2.6 T-cell effector function 
 
CD4
+
 T cells, often referred to as T helper cells, recognize antigens derived from 
extracellular sources phagocytosed, processed and presented through the MHC II-
peptide complexes on APCs. The effector response of CD4
+
 T cells consists in the 
secretion of a very large number of different cytokines, which play a fundamental role 
in the modulation of the effector functions of all the cells involved in an immune 
response. 
The activated naive CD4
+
 T cells (Th0) can differentiate into four major subsets, which 
differ for the cytokines they secrete: 
 
 Th1: they secrete IFN-γ, IL-2 (the essential T cell growth factor) and TNF-β 
(tumor necrosis factor-β) that activate CD8+ T cells and NK cells. Th1 
differentiation pathway is the response to microbes that infect or activate 
macrophages and to those that activate NK cells; the main inducer of Th1 
responses is IL-12 which is produced after TLR-ligation on DCs (Lanzavecchia 
and Sallusto, 2001). 
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 Th2: they secrete IL-4, IL-5 and IL-13 that influence B cell class switch to IgE 
and activate eosinophils. Th2 differentiation occurs in the response to helminths 
and allergens, which cause chronic T cell stimulation; the key determinant of 
Th2 cell differentiation is IL-4 (Tham et al., 2002). 
 
 Th17: they secrete the IL-17 family of cytokines and IL-22. They promote 
inflammatory responses, particularly at mucosal sites. IL-17 stimulates many 
cells of the innate immune system, as well as other types of cells, to synthesize 
IL-1, IL-6 and TNF-α, that also result in inflammation. 
 
 Treg: they inhibit or suppress the differentiation and the function of other subsets 
of CD4
+
 T cells and other cell types. Treg cells, which generally express CD25, 
suppress immune responses directed at both self-molecules and foreign antigens 
and secrete TGF-β transforming growth factor-) and IL-10. 
 
The cytokines present in the microenvironment where the activation of a CD4
+
 T cell 
occurs, drive the differentiation of the naive CD4
+
 T cell towards a particular subset and 
are generally derived from cells of the innate immune system, particularly from DCs. 
Th1 cells develop in the presence of IL-12; Th2 cells develop in the presence of IL-4; 
Th17 cells develop in the presence of TGF-β and IL-21, while Treg cells develop in the 
presence of TGF-β. 
 
Naive CD8 T cells differentiate into cytotoxic T lymphocytes (CTLs) whose main 
function is to eliminate virus infected and, in some cases, tumor cells. As for CD4
+
 T 
cells, they need co-stimulation in order to be activated upon antigen recognition.  
The classical view of how this costimulation works was described as a three-cell 
interaction, where the CD4
+
 and CD8
+
 T cells simultaneously recognize antigens 
presented on the same APC. After activation, the Th1 cells secrete cytokines such as IL-
2 which stimulate CD8 activation. 
However, since CTL responses can be induced also in the absence of Th1 cells (Deeths 
et al., 1999), another model has been proposed, divided in two steps:  
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1) the Th1 cells interact with APCs by MHC-II/peptide complex, becoming activated 
and able to condition the APCs; 
2) conditioned APCs acquire the competence to activate CD8+ T cells directly through 
up-regulation of CD80 and CD86. 
 
While Th cells mainly act by influencing the action of other immune cells, CTLs have 
the capacity to directly kill cells expressing viral or cancer antigens.  
Once activated, the CD8
+
 T cell initiates killing by attaching to the target cell; paired 
adhesion molecules expressed on the T cell and target cell surfaces help to maintain 
contact between the cells for several hours. The CTL contains granules with proteins 
with cytotoxic functions and expresses the surface molecule Fas ligand (FasL). After 
attaching to the target cell, the CTL modifies its internal structure so that these granules 
are driven close to the area of contact with the target cell and releases the contents of the 
granules by exocytosis. The major constituents of the granules involved in target cell 
killing are perforins, that form pores in the target cell membrane, and granzymes, serine 
proteases that pass into the target cell through the pores inducing apoptosis. The 
interaction of the molecule FasL on the CD8
+
 T cell with Fas, a surface molecule 
expressed on many host cells, activates the apoptosis of the target cell via a sequential 
activation of the caspases of the target cell. Once the CTL has initiated these killing 
pathways, it detaches from the dying cell to attack and kill another target. 
Once the antigen has been eliminated or the infectious agents cleared, 99% of the pool 
of activated and effector cells dies. This leaves a surviving population of memory T cell 
that is still expanded, compared to the original naive cell clone size. The memory T cell 
that survive the phase of contraction of the clone size are generally long-lived, 
frequently with a lifetime of years. They are involved in protective responses after a 
subsequent exposure to the same antigen (Coico et al., 2009; Abbas et al., 2010). 
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Chapter 3: Tumor immunology 
 
1.3.1. Immunosurveillance and cancer immunoediting 
 
Cancer arises from the uncontrolled proliferation and spread of clones of transformed 
cells. 
In 2001, the six hallmarks of cancer cells were defined as (Cancerfonden and 
Socialstyrelsen, 2001): 
1. cancer cells are self-sufficient in acquiring growth signals; 
2. they are insensitive to anti-growth signals; 
3. they are resistant to apoptosis; 
4. they have limitless replicative potential; 
5. they are able to sustain angiogenesis; 
6. they are able to invade surrounding tissues and metastasize. 
These points are sufficient for cancer growth, but several steps of tumor progression are 
supported by altered stromal cells as fibroblasts, endothelial cells and leukocytes. 
Classical cancer treatments, such as surgery, chemotherapy, radiation and hormonal 
treatment, not only lead to severe side effects but are also mainly effective only in early 
stage cancer. Therefore, there is a great medical need for alternative treatment 
strategies. 
The possibility that cancer may be eradicated by specific immune responses has been 
the impulse for many studies. 
Lewis Thomas and Macfarlane Burnet postulated the “Immunosurveillance Theory”, 
which states that a main function of the immune system is to seek out and destroy 
cancers as they arise (Burnett et al., 1970). This theory emerged from data showing that 
syngeneic mice could be immunized and reject methyl-cholantrene- and virally-induced 
tumors (Malberg et al., 2006), indicating that tumor antigens exist and can be detected 
by the immune system. The immunosurveillance theory can be validated showing that 
immunodeficiency results in an increased incidence of cancer. An increase in cancer 
incidence is also observed in immunosuppressed transplant recipients (Ratliff et al., 
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1993). However, despite immunosurveillance, cancers develop in immunocompetent 
hosts. 
It was recently suggested that inability of the immune system to eradicate tumors or 
avoidance of immunesurveillance is the seventh hallmark of cancer (Dunn G.P. et al., 
2002 and 2004; Smyth M.J. et al., 2004; Zitvogel L. et al., 2006).  
The term “cancer immunoediting” was coined to explain this phenomenon (Dunn G.P. 
et al., 2002). The cancer immunoediting model describes three phases (Figure 7): 
1.  elimination phase (immunosurveillance): the immune system targets and 
destroys antigen bearing tumor cells; 
2. equilibrium phase: the immune system applies immunologic pressure, which 
controls tumor growth, but not fully eliminates tumor cells. During this phase, 
tumor cells acquire mutations that render them less sensitive to immune attack; 
3. escape phase: immune resistant tumor cells expand to a detectable tumor. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Cancer immunoediting encompasses three process. a) Elimination; b) Equilibrium; c) Escape. 
In a) and b), developing tumor cells (blue), tumor cell variants (red), and underlying stroma and non-
transformed cells (grey) are shown; in c) additional tumor variant (orange) that have formed as result of 
equilibrium process are shown. Different lymphocyte populations are as marked. The small orange circles 
represent cytokines and the white flashes represent cytotoxic activity of lymphocytes against tumor cells 
(Dunn G.P et al., 2002). 
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1.3.2. Tumor antigens 
 
A tumor antigen is the specific target against which the immune response is generated 
after vaccination. Several tumor antigens , recognized by T cells, have been identified 
and used in clinical trials (Lee G.K et al., 2002). Tumor antigens can be categorized into 
four groups: (a) antigens unique to an individual patient‟s tumor; (b) antigens common 
to a histologically similar group of tumors; (c) tissue-differentiation antigens; and (d) 
ubiquitous antigens expressed by normal and malignant cells (Berzofsky J.A et al., 
2004). 
Due to their genetic instability, tumor cells do not express common proteins; but they 
can express tumor associated antigens (TAAs), that have low or limited expression in 
non-malignant cells.. An extensive listing of the known TAAs is available, and more are 
being discovered (Renkvist et al., 2001). They have mainly been found in melanomas 
and melanocytes as Melan-A (Coulie P.G. et al., 1994) and tyrosinase (Brichard V. et 
al., 1993), but also in other epithelial tissues, such as prostate specific antigen (PSA) 
(Corman J.M. et al., 1998). Other TAAs, such as HER-2/neu (Fisk B. et al., 1995), 
hTERT (Minev B. et al., 2000) and survivin (Andersen M.H. et al., 2001), are 
overexpressed in tumors but also expressed at lower levels in normal tissues. 
Another group of tumor antigens are tumor-specific antigens and they are uniquely 
expressed by tumor cells. Tumor specific antigens are relatively rare and among these 
are: 
1. antigens that arise from point mutations in oncogenes or tumor suppressor 
genes, such as Ras in pancreatic and colorectal cancer (Gjertsen M.K. et al., 
1998) or p53 in lung cancer (Yanuck M. et al., 1993). These antigens expose 
new and potentially immunogenic epitopes, which have never been encountered 
by the host‟s immune system and thus they can potentially be recognized by T 
cells; 
2. antigens belonging to the cancer testis family, which are the results of re-
activation of genes that are normally silent in adult tissues, such as antigens of 
MAGE, BAGE and GAGE families (Novellino L. et al., 2005); 
3. antigens derived from virally-induced tumors, that constitute almost 20% of all 
human cancers (Stewart B.W. 2003), for example the E7 antigen from HPV 
(which causes cervical carcinoma), (Eiben G.L. et al., 2003) and the EBNA2 
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antigen derived from Epstein-Barr virus (which is associated with B cell 
lymphomas) (Taylor G.S. et al., 2004). 
Sometimes, the use of the whole tumor as source of antigens is the gold standard in 
tumors where no strong antigens are available (Matera and Garetto, 2009). 
 
 
1.3.3 Tumor escape 
 
Tumors evade immune targeting also by actively suppressing immune responses. 
Mechanisms such as antigen loss, expression of inhibitory molecules, lack of 
costimulation, MHC-I downregulation, may explain the failure of an endogenous 
immune response in tumor control (Shreiber H. Et al., 2002). 
 Inhibitory cell populations: Tolerogenic DCs, ,regulatory T cells and myeloid 
derived suppressor cells (MDSCs) 
Tumor derived IL-10 and TGF- have several suppressive effects on antitumor immune 
responses (Mocellin S. et al., 2004; Teicher B.A. et al., 2007). In addition to their direct 
effects on T cells, such as inhibition of IL-2 production (Thomas D.A. et al., 2005), 
secretion of IL-10 and TGF-was reported to suppress differentiation and function of 
local DCs (Moore K.W. et al., 2005; Mou H.B. et al., 2004). The result is the presence 
of tolerogenic DCs in the tumor microenvironment, that leads to ineffective T cell 
priming and induction of T cells anergy (Steinbrick K. et al., 1999). Other factors 
contributing to the accumulation of tolerogenic DCs in tumors are macrophage-colony 
stimulating factors (M-CSF) and IL-6 (Gabrilovich D. et al., 2004). IL-10, TGF-and 
tolerogenic DCs have also been shown to promote the conversion of naive CD4
+
 T cells 
to T reg cells (Chen W. et al., 2003; Ghiringhelli F. et al., 2005). On the other hand, T 
reg cells are commonly detected in tumors and can be described as a T cell population, 
which mediate suppression of a large portion of TAA-specific T cells (Curiel T.J. et al, 
2004). Tumour progression is often associated with altered haematopoiesis, which leads 
to the accumulation of myeloid cells at the tumour site, in the blood, secondary 
lymphoid organs, and bone marrow (Bronte V et al., 2005; Serafini P et al., 2006). 
These cells, named myeloid-derived suppressor cells (MDSCs) modify the tumour 
microenvironment through key enzymes of L-Arginine metabolism: nitric-oxide 
synthase (NOS) and arginase 1 (ARG1) (Bronte V et al., 2005; Gallina, G et al., 2005). 
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The depletion of L-Arg in the microenvironment leads to inhibition of T cell 
proliferation through the down-regulation of CD3zeta-chain expression in T 
lymphocytes (Rodriguez PC et al., 2002), thus suppressing the anti-tumor immune 
response. 
 
 Loss of antigen presentation and resistance to apoptosis 
The exact mechanism that controls the downregulation of tumor antigens are not known 
in most cases; however, the propagation of antigen loss variants may be facilitated by 
epitope immunodominance. The phenomenon of immunodominance may be thought of 
as the preferential immunodetection of one or a few epitopes among many expressed on 
a given target. The theory of immunodominance, as it relates to tumor escape, predicts 
that one of the ways that antigen loss variants within a tumor are shielded from immune 
pressure is that parental tumor cells carrying the immunodominant epitope serve as a 
red flag for immune attack, thereby diverting attention from the tumor variants. Once 
the parental cells are eliminated, a new hierarchy is established among the variant 
subpopulations, and formerly immunorecessive epitopes become dominant (Khong H.T. 
et al., 2002). A tumor variant that has lost the restricting MHC class I allele while 
retaining the immunodominant antigen could cross-present this antigen to CD8
+
 CTLs 
by DCs and maintain an immunodominant response to a “phantom” target at the 
expenses of more appropriate and effective responses to other antigens (Seung S. et al., 
1993; Khong H.T. et al., 2002). Different mechanisms can lead to the total or partial 
loss of MHC-I expression, that can be produced at any step required for MHC-I 
expression, from transcription to transport to cell surface (Garcia-Lora et al., 2003). 
Most tumors seem to grow in a non inflammatory microenvironment that does not 
conduct to immune activation. Recognition of tumor antigens by DCs under these 
conditions will not lead to DCs activation and maturation. In addition, lack of 
expression of costimulatory molecules by tumor cells may lead to T cell anergy and 
suboptimal activation of NK cells. 
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Chapter 4: Apoptosis, Necrosis and Hyperthermia 
 
Homeostasis is maintained in multicellular organisms by a balance between cell 
proliferation and cell death. Several types of cell death have been described: apoptosis, 
cell death associated with autophagy, necrosis, and many other different types (Kumar 
V. et al., 2005). Apoptosis and necrosis are the two most studied types of cell death:. 
 
1.4.1 Apoptosis and necrosis 
 
Apoptosis is a pathway of cell death induced by a tightly regulated intracellular 
program: dying cells activate enzymes that degrade the nuclear DNA and nuclear and 
cytoplasmic proteins. Plasma membrane remains intact, but its structure is altered, thus 
becoming an avid target for phagocytosis. Dead cells are rapidly cleared, before their 
contents have leaked out, and therefore cell death by this pathway does not elicit an 
inflammatory reaction in the host. Apoptosis occurs physiologically in many situations, 
for example to eliminate unwanted or potentially harmful cells and cells that have 
outlived their usefulness. It is also a pathologic event when cells are damaged beyond 
repair, especially when the damage affects DNA. 
The apoptotic pathway presents a series of morphologic and biochemical characteristics, 
such as: 
 cell shrinkage: the cell is smaller in size, the cytoplasm is dense and the 
organelles, although relatively normal, are more tightly packed; 
 chromatin condensation: the chromatin aggregates peripherally, under the 
nuclear membrane, into dense masses of various shapes and sizes. The 
nucleus itself may break up, producing two or more fragments; 
 formation of cytoplasmic blebs and apoptotic bodies: the apoptotic cell 
first shows extensive surface blebbing, then undergoes fragmentation 
into membrane-bound apoptotic bodies composed of cytoplasm and 
tightly packed organelles, with or without nuclear fragments; 
 phagocytosis of apoptotic cells or cell bodies, usually by macrophages: 
the apoptotic bodies are rapidly degraded within lysosomes, and the 
adjacent healthy cells migrate or proliferate to replace the space occupied 
by the now deleted apoptotic cell (Kumar V. et al., 2005). 
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Necrosis refers to a spectrum of morphologic changes that follow cell death in living 
tissue, largely resulting from the progressive degradative action of enzymes on the 
lethally injured cells. As commonly used, necrosis is the gross and histologic correlate 
of cell death occurring in the setting of irreversible exogenous injury. Necrotic cells are 
unable to maintain membrane integrity and their contents often leak out: this may elicit 
inflammation in the surrounding tissue. The morphologic appearance of necrosis is the 
result of denaturation of intracellular proteins and enzymatic digestion of the cell. The 
necrotic cells show the following features: 
 increased eosinophilia attributable to loss of the normal basophilia 
imparted by the RNA in the cytoplasm; 
 a more glassy homogeneous appearance than that of normal cells and the 
cytoplasm becomes vacuolated; 
 non-specific breakdown of the DNA: the basophilia of the chromatin 
may fade (karyolysis); nuclear shrinkage and increased baspophilia 
(pyknosis); DNA condenses into a solid, shrunken basophilic mass 
(karyorrhexis). With the passage of time the nucleus of the necrotic cell 
totally disappears (Kumar V. et al., 2005). 
 
Apoptotic process can progress to secondary necrosis in situations where clearance by 
scavengers does not operate and so the complete apoptotic program can fully evolve. 
This is the case of some physiological situations where apoptotic cells are shed into 
ducts or into territories topologically outside the organism (like the gut or the airways 
lumen) or in the lumina of the acini, where the chances of encountering scavengers are 
small. Moreover, extensive secondary necrosis has been described in multicellular 
animals in situations of massive apoptosis that surmounts the available scavenging 
capacity, and when this capacity is directly affected by detrimental effects on scavenger 
cells or by processes that affect molecules involved in phagocytosis of apoptotic cells. 
The above observations support the conclusion that the complete apoptotic process in 
multicellular animals is genetically controlled by an intrinsic program that includes an 
autolytic termination by secondary necrosis, which makes that process self-sufficient 
leading to self-elimination when scavengers are not available. The above observations 
also show that there is an obvious and important functional limitation: depending on an 
assisting scavenger cell, this mechanism fails if that cell is not available or is defective, 
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in which case apoptosis will proceed to its completion, leading to the secondary necrotic 
outcome. One mechanism for the genesis of pathogenic consequences of extensive or 
persistent apoptotic secondary necrosis is the leakage of cytotoxic, pro-inflammatory 
and immunogenic molecules by the autolysing cells. These molecules include Danger 
Associated Molecular Pattern (DAMPs), and their release may be beneficial in regards 
to immunogenic cell death in tumors. However, necrosis-associated release of DAMPs 
often has pathological pro-inflammatory and immunogenic consequences, contributing 
to the pathology frequently associated with extensive or persistent secondary necrosis. 
Release of lysosomal proteolytic enzymes and the oxidative burst occurring during 
secondary necrosis may participate in the generation of DAMPs by modifying original 
cell components, that are later released due to the eventual rupture of the plasma 
membrane. Among pro-inflammatory and immunogenic DAMPs are proteases, 
nucleosomes consisting of double-stranded DNA and histones, S100 calgranulin 
proteins, high mobility group box-1 (HMGB-1) protein, proteolitically processed 
autoantigens, and urate crystals. Secondary necrotic cells can be phagocytosed by 
scavengers in vivo and this phagocytosis often is pro-inflammatory and immunogenic, 
and thus may represent another mechanism for the genesis of pathogenic consequences 
of secondary necrosis. On the other hand, secondary necrosis affecting tumor cells has 
recently gained an additional relevance due to its recognition as a process with likely 
beneficial implications in anticancer therapies by facilitating the activation of the 
immune system and consequently the clearance of tumor cells. 
Anticancer chemotherapy and radiotherapy are largely mediated by apoptosis. It has 
been reported that, after treatment with some chemotherapeutic agents or ionizing 
irradiation, tumor cells may become highly immunogenic when injected into 
immunocompetent mice (Kepp O. et al., 2009). Several observations have been 
accumulated suggesting that such immunogenicity is associated to the progression to 
secondary necrosis of therapy-induced apoptotic tumor cell death and to the release by 
secondary necrotic tumor cells of the DAMP molecule HMGB-1: tumor cells treated in 
vitro with some apoptogenic chemotherapeutic agents or radiotherapy release HMGB-1 
protein, and secondary necrosis was suggested to be the mechanism for that release. As 
discussed elsewhere (Brusa D. et al., 2008), clearance of apoptotic cells may be 
insufficient during therapy-induced apoptotic tumor cell death in vivo, resulting in the 
accumulation of secondary necrotic cells. 
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It has been found that secondary necrotic tumor cells stimulate DCs (Buttiglieri S. et al., 
2003), and thus are immunogenic. The presentation of tumor antigens by mature DCs 
leads to CD4
+
 and CD8
+
 T cell activation. HMGB-1 released by secondary necrotic 
tumor cells is recognized by DCs which prime CD4
+
 and CD8
+
 T cells (Silva M.T. et 
al., 2010). 
 
 
1.4.2 Hyperthermia and Heat Shock Proteins (HSPs) 
 
The use of hyperthermia in the therapy of cancer has been an object of clinical interest 
for many years. Hyperthermia seems to be particularly effective in combination with 
radiotherapy and/or radioimmunotherapy. The molecular mechanism by which 
hyperthermia leads to radiosensitization is not clear; however, activation of early 
response genes, heat shock factors, and subsequently Heat Shock Proteins (HSPs) has 
been proposed to play a role. HSPs constitute a superfamily of distinct proteins that are 
operationally named according to their molecular mass. Most HSPs are expressed 
constitutively and are further induced under stress conditions, including temperature 
increase. HSPs are chaperones that assist newly synthesized polypeptides during protein 
folding and translocation to intracellular compartments and are important in the 
clearance of unfolded or improperly folded proteins. In the context of immune systems, 
HSPs transfer antigenic peptides, thereby facilitating peptide presentation to CD8
+
 T 
cells (Shi H. et al., 2006). 
Mammalian HSPs have been classified into five families according to their molecular 
size: HSP100, HSP90, HSP70, HSP60 and small HSPs (15-30 kDa) including HSP27. 
Each family of HSPs is composed of members that are expressed either constitutively or 
regulated inductively, and that are targeted to different sub-cellular compartments. 
HSP27 and HSP70 are the most strongly and universally induced chaperones. Under 
normal conditions, HSP70 proteins function as ATP-dependent molecular chaperones 
that assist the folding of newly synthesized polypeptides, the assembly of multi-protein 
complexes and the transport of proteins across cellular membranes. HSP70 contains two 
distinct functional regions: a peptide binding domain (PBD) and the amino-terminal 
ATPase domain (ABD). Under stressful conditions, elevated HSP70 levels allow cells 
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to cope with increased concentrations of unfolded or denatured proteins (Garrido C. et 
al., 2006). 
HMGB-1 is a relatively small protein of 215 amino acid residues. Structurally, the 
protein is organized into three distinct domains: two tandem HMG box domains (A box 
and B box), which are spaced by a short flexible linker, and a 30 amino acid-long acidic 
C-terminal tail. As structural units, HMG boxes are well conserved throughout 
evolution and are characterized by three α-helices, which are arranged in an L-shaped 
configuration. In the nucleus, HMGB-1 is a non-histone DNA-binding protein and 
serves as a structural component to facilitate the assembly of nucleoprotein complexes. 
The intracellular as well as extracellular function of HMGB-1 is further regulated by 
post-translational modification of the protein (Sims G.P. et al., 2010). HMGB-1 can also 
be secreted by different cells, like monocytes/macrophages, and plays important roles in 
inflammation and tumor metastasis (Muller S. et al., 2001); it is also passively released 
by necrotic cells, though not by apoptotic cells, triggering inflammation (Youn J.H. et 
al., 2006). In fact, once released, HMGB-1 is able to activate several cells involved in 
the immune response (i.e. DCs) or inflammatory reactions, and can act as a cytokine 
itself (Muller S. et al., 2001). 
 
 
Chapter 5: Cancer immunotherapy 
 
1.5.1 Active and passive immunotherapy 
 
Active specific cancer immunotherapies, or “cancer vaccines”, aim at the induction of 
tumor antigen-specific immune responses, both cellular and humoral, and also at the 
generation of immunological memory. Using non-specific immune stimulators, such as 
cytokines (IFN-α, IL-2 or CpG- Kempf R.A. et al., 1986; Lotem M. et al., 2004; 
Kochenderfer J.N. et al., 2006), tumor-specific immune responses can be further 
enhanced. Despite the strong antitumor immune responses observed in animal models, 
limited responses have been observed in clinical trials. 
Passive cancer immunotherapy administers ready-made effector molecules or cells 
(tumor antigen-specific antibodies or effector T cells). 
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In contrast to active cancer immunotherapy, the passive approach does not always 
require an active participation by the patient‟s immune system. It is short-lived and 
relies on repeated administration of the effectors. 
Whilst the majority of the active immunotherapeutic approaches are still in preclinical 
evaluation or in early phase of clinical trials, several of the antibody-based therapies 
have resulted in very successful and clinically available agents, such as 
trastuzumab(that targets the Her-2 antigen expressed on breast cancer cells (Goldenberg 
M.M. et al., 1999), or the anti-CD20 antibody rituximab (used in B lymphoma treatment 
(Anderson D.R. et al., 1997). 
Another technique of passive specific immunotherapy is adoptive transfer of effector T 
cells. This involves isolation of patient T cells, either from the tumor or from the blood, 
that after ex vivo processing are re-administered to the patient. This approach 
demonstrated clinical responses in melanoma patients (Mackensen A. et al., 2006). 
A schematic overview of active and passive cancer immunotherapy is illustrated in 
Figure 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Active and passive cancer immunotherapy. Active cancer immunotherapy comprises tumor 
antigen uptake by APCs (1), epitope (peptide) presentation to CD4+ T cells (2), cytokine release (3), B 
cell activation (4) and antibody production (5), leading to lysis of tumor cells including different passive 
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alternatives like activation of immune effectors cells-ADCC (6), activation of complement cascade-CDC 
(7) or unspecific attack by cytotoxic T lymphocytes (8). Schuster et al., 2006. 
 
 
1.5.2 Pancreatic cancer immunotherapy 
 
In many cancers it may be difficult to generate tumor reactive T cells due to the 
immunosuppressive factors produced by tumor cells. The expression of FasL or RCAS-
1, which either induce apoptosis or inhibition of T cell proliferation, was reported in 
pancreatic cancers (Pernick NL. et al., 2002). RCAS-1 was found expressed in most 
pancreatic cancers and high expression is correlated with poor survival. 
Some antigens were found to be recognized by CD8
+
 T cells. Using sera from 
pancreatic cancer patients, Kawakami et al. have isolated 4 pancreatic cancer antigens: 
KU-PAN-1, KU-TES-1 and two DNA mismatch repair enzymes. 
Passive immunotherapy with high doses of activated antitumor lymphocytes can be 
insufficient to induce an immune response able to cause tumor regression in 
immunocompromised patients with a large tumor burden. The most important problems 
of adoptive transfer in vivo are the maintenance and the accumulation of T cells in 
tumor tissues. However, it is now possible to generate tumor-reactive T cells from the 
PBMCs of cancer patients by in vitro stimulation, using identified tumor antigens 
(Rivoltini L. et al, 1995). Tumor reactive T cells from patients pre-immunized with 
tumor antigens were generated more efficiently, suggesting that combined use of active 
and passive immunotherapy could be the best solution. 
For example, the use of autologous DCs pulsed with tumor antigens as an active 
immunotherapy to generate a cytotoxic immune response. Several studies have 
documented the generation of antitumor CTL cells after vaccination with tumor antigen-
loaded DCs (Takahashi H. et al., 1993). Immunization with DCs pulsed with hTERT or 
p53 resulted in better antitumor effects than direct peptide administration (Tokunaga et 
al., 2005). In immunization trials using DCs pulsed with tumor lysates or synthetic 
peptides, tumor regression was observed in patients with prostate cancer, colon cancer 
and B-cell lymphoma (Nestle et al., 1998). A decrease of soluble tumor markers in the 
serum was observed in a patient with a pancreatic neuroendocrine tumor, following 
immunization with DCs pulsed with autologous tumor lysates (Schott et al., 2001).  
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Chapter 6: Humanized mice for preclinical research 
 
Small animal models have been very helpful to investigate immunological mechanisms 
but certain limitations are unavoidable because of species-specific differences to 
humans. 
Mice bearing severe immunodeficiecies (SCID) and harbouring human cells or tissues 
are frequently referred to as “humanized mice”. They are a promising tool for study 
complex mechanisms in human biology and they at least may partly overcome these 
species-specific differences. Mice bearing human immune systems have been developed 
to investigate immune-mediated disease pathogenesis (Melkus et al., 2006; Shultz et al., 
2007) , allogeneic tissue rejection and tolerance in vivo (Pober et al., 2003). 
However, humanized mice remain a difficult field of research and a relevant model for 
preclinical evaluation of human T cells in vivo is currently lacking. 
 
 
1.6.1 Protocols of “humanization”: aspects and problems 
 
Two main ways of “humanization” have been developed: the SCID-hu model, which 
consists of engrafting immunocompromised mice with human fetal tissues, and the hu-
PBL-SCID model, which is derived from intraperitoneal injection of human peripheral 
blood lymphocytes (PBLs). 
About 20 years ago, the original “SCID-hu” model was developed by McCune et al., 
using C.B-17-SCID mice (an immunocompromised mouse strain which has not 
essential adaptive immune system) as recipients for human hematopoietic tissues, 
including fetal liver, bone and or thymus originating from human fetuses (McCune et 
al., 1988; Namikawa et al., 1990; Kyoizumi et al., 1992). Engrafted human 
hematopoietic tissue resulted in low levels of human T and B cells that were able to 
produce a primary antibody response when autologous fetal skin, serving as an 
additional source of DCs, was co-engrafted along with thymus, bone morrow and lymph 
node (Carballido et al., 2000). The low numbers of mature human cells that repopulate 
the lymphoid tissues of SCID-hu mice makes this model inappropriate to study the 
mature functional human immune system (Krowka et al., 1991). 
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However, adoptive transfer of peripheral blood mononuclear cells (PBMCs) in the same 
mouse strain (hu-PBL-SCID model) supported low levels of engrafment of T, B and 
DCs (Mosier et al., 1988). Despite the numerous studies performed in the hu-PBL SCID 
model, results dealing with reconstitution of SCID mice by human engrafted PBLs were 
not consensual in terms of number and characteristic of human cells repopulating mice, 
depending both on screened organs and time of engrafment (Mosier et al., 1988; Tary-
Lehmann et al., 1992; Martino et al., 1993). Moreover, a still controversial point is the 
existence of a graft-versus-host (GvH) reaction in these chimeras, supported by 
histological and functional studies (Murphy et al., 1992; Hoffmann-Fezer et al., 1993). 
This is one of the most critical point of the “humanized mouse models”: if this 
xenoreaction effectively occurred, it should influence the human T-cell repertoire. 
However, C.B-17-SCID animals are still significantly resistant to adoptive transfer of 
PBLs; indeed, further studies showed that resistance to adoptive transfer of human cells 
was reduced in animal treated with anti-asialo GM1, which depletes NK cells or in C.B-
17-SCID animals that have the “beige” mutation that impairs NK-cell function (Murray 
et al., 1994; Christianson et al., 1996). 
Technical advances, such as the transfer of isolated hematopoietic stem cells (HSCs) in 
newborn or adult C.B-17-SCID and NOD-SCID mice (Lapidot et al., 1992; Pflumio et 
al., 1996) and the development of more severely immunodeficient mouse strains lacking 
adaptive and innate immune responses, as Rag2 
-/-
 -chain -/- mice (Goldman et al., 1998; 
Mazurier et al., 1999), have enhanced the applicability of humanized mice reducing the 
risk of GvH reactions and increasing the level of human cells engrafted. 
 
 
1.6.2 Rag2 
-/-
 -chain -/- mice 
 
Rag2 
-/-
 -chain -/- mice were developed in 1998 by Schultz et al. In these mice the 
homologous genes coding for the “recombination activating gene 2” (RAG2), involved 
in the recombination of V(D)J sequences of the T and B cells receptors) are deleted on 
both homologous chromosomes, as well as the common -chain genes encoding the 
common cytokine receptor  chain. The results of these double knock out is a drastically 
absence of B, T cells and NK cells functions. Compared to other SCID mice, they have 
the advantage of a relatively stable phenotype without the development of spontaneous 
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tumors over time (van Rijn et al., 2006). In 2004, Traggiai et al injected intra-
hepatically newborn Rag2 
-/-
 -chain -/- mice of the BALB/c background with human 
cord-blood hematopoietic stem cells and, after 4, 8 and 12 weeks, they monitored 
engraftment and reconstitution of injected mice. They reconstituted a human adaptive 
and functional immune system in vivo with no evidence of GvHD (Traggiai et al., 
2004).  
On the other hand, intravenous injection of huPBMCs containing 15 million fresh T 
cells into adult Rag2 
-/-
 -chain -/- mice of C57BL/6 background leads to such a high 
chimerism that lethal GvHD reactions occur within 3 weeks in greater than 80% of mice 
(van Rijn et al.,2003). However, Van Rijn et al showed that this model is characterized 
by an antigen-driven process, with xenoreactivity as the stimulus for shaping the human 
T-cell repertoire (van Rijn et al., 2006). 
So far, despite some unsolved problems , the huPBMC- Rag2 
-/-
 -chain -/-  model can be 
considered the most sensitive and clinically relevant model for the in vivo analysis of 
human T cells. 
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II. Aims of the study 
 
Pancreatic cancer is one of the most aggressive malignant cancers, due to advanced 
stage at diagnosis, early systemic dissemination and poor response to chemotherapy or 
radiation therapy. The failure of conventional therapeutic options has motivated the 
search for immunotherapeutic approaches. In fact, some correlations between pancreatic 
cancer and immune system have been described: local and systemic alterations of 
effector T cell responses have been recognized in pancreatic cancer patients and 
pancreatic cancer cells produce immunomodulatory cytokines such as TGF-, with 
immunosuppressive effects. 
The initial aim of this study was the reconstitution of newborn immunodeficient mice 
with intrahepatically injection of bone marrow-derived leukocyte precursor CD34+ cells 
from pancreatic cancer patients, in order to obtain patient-specific humanized mice, to 
be implanted subcutaneously or orthotopically with pancreatic tumor cells from the 
same patient. This setting should allow to study in vivo the cross-talk between tumor 
and immune system and to evaluate immunotherapeutic approaches much better than in 
in vitro settings. 
So far, we had some burocratic problems in the acquisition of bone marrow-derived 
leukocyte precursor CD34+ cells from pancreatic cancer patients as well as from 
healthy donors. Therefore, waiting for bone marrow, we reprogrammed the aims of the 
study as:  
1- the establishment of protocols of delivery of human PBMCs to Rag2 -/-  chain -
/-  immunodeficient mice, starting from either newborn or adult mice; 
2-  the development of an adoptive cell transfer (ACT) therapy based on human T 
lymphocytes activated in vitro by autologous DCs loaded with necrotic 
pancreatic tumor cells after hyperthermia or UVC treatment, to be delivered to 
Rag2 -/-  chain -/-  immunodeficient mice bearing the same human pancreatic 
tumor,,from which the necrotic cells used for DC loading were derived. 
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III. Materials and methods 
 
3.1 Reconstitution of a human immune system in Rag2 
-/-
  chain-/- mice 
 
Rag2
-/-
 -chain-/- mice were purchased from TACONIC Farm (Hudson, NY, USA) and a 
colony was propagated and maintained in the facility of University of Verona. 
Reconstitution with human PBMC-derived cells from healthy donors was attempted in 
both newborn and adult (8 weeks of age) Rag2
-/-
 -chain-/- mice.  
Newborn animals (n=33) were -irradiated after birth (200 cGy) and, the day after, 
injected intrahepatically with 10-20 millions of PBMCs.  
Adult animals (n=8) were divided in four groups, -irradiated (0-200-300 and 600 cGy) 
at day 0 and inoculated at day 1 by intraperitoneal injection (i.p.) with 50 millions 
PBMCs. Another group of adult animals (n=6), not irradiated, was injected i.p. with 
Percoll gradient-separated human lymphocytes from healthy donors.  
The presence of cells of the human immune system was monitored: 
 by FACS analysis on peripheral blood of mice 4 or 8 weeks after injection and 
  at the end of the experiments, when mice were sacrified and organs were 
collected for FACS analysis and immunohistochemistry. 
 
 
3.2 Cell lines 
 
The human PaCa-44, PT-45, PANC-1 and PANC-2 cell lines, all derived from primary 
pancreatic adenocarcinoma and HLA-A*0201 homozygous have been largely studied 
by Prof. Aldo Scarpa and coworkers (Department of Pathology and Diagnostics, 
University of Verona, Italy), together with several other cell lines of similar origin also 
for the expression of immunogically relevant molecules (Scupoli MT et al., 1996).  
Cells were maintained in RPMI-1640 (GIBCO INVITROGEN Corporation, San Diego, 
CA, USA) supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS 
EUROCLONE, Pavia, Italy) and L-glutammine 1 mM (BIOCHROM AG, Cambridge, 
UK). Cell cultures were incubated in a humidified incubator at 37°C and 5% CO2 
atmosphere. To be propagated and for analysis, cells were detached by trypsin treatment 
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(0.05% trypsin at 37°C for 5 minutes, GIBCO INVITROGEN Corporation, San Diego, 
CA, USA) for use in culture. 
 
 
3.3 Immunofluorescence and cytofluorimetric analysis 
 
PaCa-44, PT-45, PANC-1 and PANC-2 cells were monitored by direct and indirect 
immunofluorescence and flow cytometry on a FACSCalibur (BD PHARMINGEN, 
Milan, Italy) for the maintenance of surface expression of MHC-I and –II, co-
stimulatory and adhesion molecules, using the following specific monoclonal 
antibodies: B9.12.1, specific for human MHC-I monomorphic determinants; D1.12, 
specific for the MHC-II molecule HLA-DR (Ref Scupoli et al.); anti-human CD54-PE 
(BD-PHARMINGEN, Milan, Italy), specific for the human ICAM-1 (Intercellular 
Adhesion Molecule-1); anti-human CD58-FITC (BD-PHARMINGEN, Milan, Italy), 
specific for human LFA-3 (lymphocyte function-associated antigen 3); anti-human 
CD80-PE (BIOLEGEND, San Diego, CA, USA), specific for the human B7-1 
molecule, and anti-human CD86-PE (BIOLEGEND, San Diego, CA, USA), specific for 
human B7-2 molecule. 
FACS analysis of cells from peripheral blood of mice and of cells from cross-priming 
experiments was performed with anti-CD45-APC (pan-leukocyte marker), anti-CD3-
PE-Cy7 (for T cells), anti-CD8-FITC (for CD8
+
 T cells), anti-CD4-APC (for CD4
+
 T 
cells), anti-CD14-PE (for monocytes), anti-CD19-FITC (for B cells) and anti-CD56-
FITC (for NK cells). All these antibodies were purchased from BIOLEGEND, San 
Diego, CA, USA.  
Human DCs were stained with anti-CD1a-FITC, anti-CD14-PE, anti-CD80-PE or -APC 
and anti-CD83-FITC (BIOLEGEND, San Diego, CA, USA). Specific control isotypes 
were used in direct immunofluorescence (BIOLEGEND, San Diego, CA, USA). 
10‟000 events were acquired for each sample processed. Results were analyzed using 
the DIVA Software (BD Biosciences, Bedford, MA, USA) and images were processed 
by the Flow Cytometry Analysis Software FlowJo. 
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3.4 Killing of tumor cells and analysis of tumor cell death parameters 
 
PaCa-44, PT-45, PANC-1 and PANC-2 cells received the following treatments: -
irradiation with a 
137
Cs -irradiator source (13000 cGy), 56°C by direct immersion of 
collecting tubes with the cells into a temperature-controlled water bath for 15, 30, 60 or 
120 minutes, UVC (3.6J/cm
2
) using an UVC lamp PLS 9W/2P, W 2.3 (PHILIPS, 
Milan, Italy) for 10, 20, 30 or 60 minutes, or Gemcitabine (1M) (LILLY, Indianapolis, 
IN, USA) for 72 hours. 
After 4 or 20 hours from the above treatments, 1 x 10
6
 tumor cells were stained with 
Annexin V(Ann V)-FITC and Propidium iodide (PI)-PE (ROCHE Diagnostics 
Corporation, Indianapolis, IN, USA) and they were analyzed by flow cytometry. 
 
 
3.5 Analysis of DAMPs and TGF- molecules release 
 
At the indicated times, cells were centrifuged and the supernatants were collected and 
frozen at -20°C. For lysates, 1 x 10
6
 alive tumor cells were treated with RIPA buffer (50 
mM Tris-HCl, pH 7.4; 150 mM NaCl; 1% NP-40) and protease inhibitors (SIGMA-
ALDRICH, St. Louis, MO, USA)  and then they were frozen at -80°C. 
The release of the HSP-70 and HMGB-1 DAMPs molecules and TGF-was evaluated 
on collected supernatants by enzyme-linked immunoassorbent assay (ELISA) kits, 
according to manufacturer‟s instructions. The range of sensitivity of the HSP-70 assay 
was 4.68-150 ng/ml.( R&D Systems, Minneapolis, MN, USA); the range of sensitivity 
of the HMGB-1 assay was 2.5-80 ng/ml (IBL INTERNATIONAL GMBH, Hamburg, 
Germany); the range of sensitivity of the TGF-immunoassay was 31.2-2‟000 pg/ml 
(R&D Systems, Minneapolis, MN, USA) 
 
 
3.6 Generation of immature Dendritic Cells (iDCs) 
 
Immature DCs were generated from Buffy coats of HLA-A2
+
 blood bank donors of 
Policlinico G.B. Rossi, Verona, Italy, according to standard protocol (Markowicz, S., 
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and E. G. Engleman. 1990). Peripheral blood mononuclear cells (PBMCs) were isolated 
by standard density gradient centrifugation (Ficoll Paque
TM
-PLUS, GE Healthcare, 
Chalfont St. Giles, UK). They were washed twice with Phosphate-Buffered Saline 
(PBS) and then monocytes and lymphocytes were separated by a density Percoll
TM
 
gradient centrifugation (GE Healthcare, Chalfont St. Giles, UK). Monocytes were 
plated in 24-well tissue culture plates (GREINER BIO-ONE Labortechnik, 
Frickenhausen, Germany) at a concentration of 3-3,5 x 10
6
 cells in 1 ml of RPMI 1640 
medium supplemented with 2% FBS and 1mM L-glutammine. After 1 hour, not 
adherent cells were separated from the rest of mononuclear cells by gentle washing. The 
remaining (adherent) cells were cultured for 5 days with RPMI 1640 medium 
supplemented with 10% FBS and 1 mM L-glutammine, in the presence of human 
granulocyte/macrophage colony-stimulating factor GM-CSF (final concentration: 50 
ng/mL) and IL-4 (final concentration: 20 ng/mL) (PEPROTECH, Rocky Hill, NJ, 
USA).After 5 days they were collected and used as immature DCs.  
 
 
3.7 Maturation assay of human DCs co-cultured with treated tumor cells 
 
Four hours after the treatments indicated above, PaCa-44, PT-45, PANC-1 and PANC-2 
cells were mixed with iDCs (2:1 ratio) and after 24 hours of incubation, DCs were 
exposed to a new medium containing the maturative cytokines TNF- (final 
concentration: 10 ng/ml), IL-1 (final concentration: 1 ng/ml), IL-6 (final concentration: 
10 ng/ml) (PEPROTECH, Rocky Hill, NJ, USA) and PGE2 (final concentration: 
1g/ml) (SIGMA-ALDRICH, St. Louis, MO, USA). The effect of incubating the tumor 
with iDCs was studied before and 48 hours after the addition of maturative cytokines by 
FACS analysis using anti-human CD80-PE, anti-human CD83-FITC direct antibodies 
and anti-human MHC-II primary antibody (see 3.2). A total of 10‟000 cells were 
acquired for each sample. 
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3.8 Uptake of dying tumor cells by iDCs 
 
PaCa-44, PT-45, PANC-1 and PANC-2 cells were red-stained with PKH26-PE 
(SIGMA-ALDRICH, St. Louis, MO, USA) according to the manufacturer‟s 
instructions, before receiving the above killing treatments. Four hours later, tumor cells 
were incubated with iDCs (2:1 ratio) in human GM-CSF and human IL-4-containing 
medium at 37°C (see 3.5). After 24 hours, the mixed culture was stained with anti-
CD80-APC (see 3.2). Phagocytosis of tumor cells by iDCs was assessed by flow 
cytometric analysis as the percentage of double-stained (PE
+
/APC
+
) cells on a total of 
10‟000 events. 
For microscopy analysis of tumor engulfment, DCs and tumor cells cultured and stained 
as described above (for DCs, we used anti-human CD1aFITC-see 3.3) were mounted on 
a coverslip in Acqueous Gel Mounting (SIGMA-ALDRICH, St. Louis, MO, USA) and 
the fluorescence was assessed by FITC and TRITC filters on a fluorescence microscope 
(Olympus BX41) equipped with a Leica DFC320 camera and Leica Qwin Software. 
Images were processed by Adobe Photoshop 7.0. 
 
 
3.9 Cross-priming of T lymphocytes with autologous tumor-loaded DCs 
 
PaCa-44, PT-45, PANC-1 and PANC-2 tumor cells, not-treated or treated at 56°C or 
with UVC, were mixed with iDCs (2:1 ratio) and after 24 hours of incubation, DCs 
were exposed to a new medium containing the maturative cytokines TNF-, IL-1, IL-6 
and PGE2 (see 3.7). The day before the first stimulation, lymphocytes of the same donor 
were thawed and plated in a large flask with complete medium in presence of human 
IL-2 (final concentration: 20U/ml). After 48 hours, mDCs were added to autologous T 
lymphocytes at a ratio of 1:10 in 24-well tissue culture plates. Human IL-2 (final 
concentration: 20U/ml) was added to the cultures after 24 hours and the procedure has 
been repeated weekly, for up to two total stimulations. For cross-priming cultures, we 
used RPMI 1640 medium supplemented with 10% FBS, 1 mM L-glutammine and 10 
ml/L Penicillyn/Streptomycin (SIGMA-ALDRICH, St. Louis, MO, USA). 
III MATERIALS AND METHODS 
 
55 
 
Generation of specific anti-tumor response was evaluated five days after the last 
stimulation as release of human IFN- in ELISA assay and in measure of CTL-specific 
cytotoxicity in standard 
51
Cr release assays.  
 
 
3.10 Human IFN- ELISA assay 
 
Supernatants of cross-priming co-cultures were collected 5 days after the last 
stimulation and the release of human IFN- was assessed in ELISA assay (R&D 
Systems, Minneapolis, MN, USA). Briefly, 100 μl of samples were incubated in a 
coated Microtiter Plate with the detection antibody for 2 hours; then we added of 
streptavidin-HRP solution for 30 minutes and we measured the absorbance at 450 nm 
(reference-wavelength: 650 nm). The range of sensitivity of the assay was 15.6-1000 
pg/ml. 
 
 
3.11 
51
Cromium release cytotoxicity assays 
 
The cytotoxicity of lymphocytes from cross-priming co-cultures were measured in a 
standard 
51
Cr release assay. Due to the very low cytotoxic activity elicited in the initial 
steps of the immunization protocol, a 50:1 effector:target ratio was chosen as the 
reference ratio for all the cytotoxicity experiments performed. 
Briefly, cross-priming co-cultured cells were harvested and used as effectors against 
wild type (w.t.) PaCa-44, PT-45, PANC-1 and PANC-2 target cells labelled with 
51
Cr 
Na Chromate (PERKINELMER Life Sciences Inc. Boston, MA, USA), in a 4 hours-
incubation standard 
51
Cr release assay. When indicated, targets were kept at 4°C for 20 
minutes with the anti-human MHC class I blocking mAb W6/32 (SEROTEC, DBA 
Italia s.r.l., Milan, Italy), 25μg/ml, before being used as targets. 
The 
51
Cr release was measured in the supernatants of co-cultures; the percentage of 
specific lysis was calculated according to the formula: % Specific lysis = [(experimental 
cpm - spontaneous cpm) / (maximal cpm - spontaneous cpm) x 100]. CPM was the 
acronym for counts per million. 
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3.12 Adoptive cell transfer (ACT) of in vitro activated T cells  
 
Rag2
-/-
 -chain-/- mice (n=4/group) were injected subcutaneously (s.c.) with alive PaCa-
44 or PT-45 tumor cells (2,5 x 10
6
 cells/mouse) and 4 days later they were 
intravenously (i.v.) or intraperitoneally (i.p.) transferred with human lymphocytes (5 x 
10
6
cells/mouse) stimulated twice in vitro by cross-priming with DCs loaded with the 
corresponding necrotic tumor cell as reported above (See 3.9). Mice were injected i.p. 
with recombinant human IL-2 (30‟000U/mouse) twice a day for three consecutive days 
for i.v. ACT and once for i.p. ACT, according to current protocols (Dolcetti et al., 
2010). 
Healthy state of mice and tumor progression were evaluated three times a week; when 
tumor diameter was 1-1,5 cm, mice were sacrified and peripheral blood, tumor and 
organs were collected for FACS analysis (see 3.3) and immunohistochemistry assays. If 
signs of pain and fatigue became evident in the animals earlier, they were sacrified 
immediately. We evaluated tumor volumes considering tumor cells as growing s.c. as a 
sphere (cm
3
). All in vivo experiments are part of a Research Protocol already notified to 
the Italian Ministry of Health on April 16
th
 2008, Protocol n.22 /2008. 
 
 
3.13 Immunohistochemistry of organs and PaCa-44 and PT-45 tumor tissues 
of mice 
 
Tumor and organs of control and treated mice were fixed in buffered formalin 
(Mondial, Italia) for 24h and then they were paraffin-embedded following standard 
protocols (Chilosi et al., 2003). Serial sections of 2,5-3 µm thickness were cut with 
microtome and immunostained with hematoxilin & eosin (H&E) or a monoclonal 
antibody recognizing human CD45+ cells (Dako, Milan, Italy). When this marker was 
positive, human markers for CD3+ cells, CD4+ cells, CD8+ cells, CD20+cells , 
CD138+ cells, Ki67 and Cytokeratin-8 were also used (Dako, Milan, Italy).  
All samples were processed using a sensitive avidin-streptavidin-peroxidase technique 
(Biogen San Ramon, CA, USA) in an automated staining system (GenoMX i6000, 
BioGenex).  
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3.14 Statistical analysis 
 
Data are expressed as mean value of three different experiments ± standard deviation 
(SD). One-way ANOVA and Holm-Sidak test for multiple comparison were used to 
compare parametric variables among multiple groups, and, finally, Student‟s t test was 
used to compare parametric variables between two groups. The Shapiro-Wilk test was 
preferred to test normal distribution of a numeric variable. In any case, differences were 
considered statistically significant for P values <0.05. 
For in vivo experiments, tumor incidence was defined as the time from the inoculation 
of the tumor to the appearance of a palpable mass. Overall Survival (OS) was defined as 
the time from the inoculation of the tumor to death of the animals. Tumor growth rate 
was defined as the time from the tumor onset to a mass diameter of 1-1,5 cm.  
Tumor incidence and OS curves were calculated according to Kaplan and Meier, and 
differences between murine subgroups were tested using the log-rank test.  
P value ≤ 0.05 was considered as statistically significant. 
Statistical analyses were performed using STATA IC v.10.1 (StataCorp, College 
Station, TX) for Microsoft Windows®. 
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IV. Results 
SECTION I 
 
Attempts to reconstitute a human immune system in Rag2
-/--chain-/-
immunodeficient mice using peripheral blood mononuclear cells (PBMCs) 
 
To study the cross-talk between human cancer and immune system and to test in vivo an 
immunotherapeutic strategy using DCs loaded with hyperthermia-treated cancer cells, 
we tried to set up the conditions for obtaining a “humanized mouse model” displaying 
many features of human immune system. The goal was to reconstitute the human 
immune system of pancreatic cancer (PaCa) patients in severely immunodeficient mice, 
by means of intrahepatically delivery to newborns of hematopoietic CD34+ human bone 
marrow-derived immune precursor cells. These mice would be the ideal “container” for 
the xenograft of PaCa derived from the same patients who donated the bone marrow, in 
order to obtain a mouse model allowing to study the tumor-immune system cross-talk.  
In the animal facility of the University of Verona, we have generated a colony of Rag2 
-
/--chain-/-immunodeficient mice (double knockout mice of the C57BL/6J x 
C57BL/10SgSnAi background), with severe combined immunodeficiency (SCID) 
(hereafter named SCID mice), starting with 5 females and 5 males purchased from 
Taconic animal models (New York‟s River Valley, NY USA), and it took some months 
due to a 25% mortality in newborns (in pathogen free conditions and not treated). To 
improve engrafment, according to literature, SCID mice should be irradiated before 
injection of human cells, to eliminate a residual host immune activity due to the 
presence of NK, NKT, cells of the myelo-monocyte lineage and to create room for the 
grafting of human cells. Therefore SCID mice were exposed to sublethal irradiation 24 
hours after birth with a Cesium 137 source, and it took time also to set up the irradiation 
protocol. The effects of different times of exposure to the Cesium 137 source were 
monitored by FACS analysis on irradiated mice at 4 weeks after irradiation, compared 
to untreated, littermate control mice.  
Since initially we could not obtain bone marrow from healthy donors as well as from 
PaCa patients, we carried out experiments of reconstitution with peripheral blood 
mononuclear cells (PBMCs) from healthy donors, described here.  
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Two different protocols of reconstitution with human PBMCs, using either newborn or 
adult Rag2
-/-
 -chain-/- immunodeficient mice were attempted: 
i) PBMCs inoculation in sublethally irradiated newborn animals. Newborns were 
intrahepatically injected with 10-20 millions PBMCs 24 hours after sublethal 
irradiation.    
ii) PBMCs inoculation in not-irradiated or sublethally irradiated adult animals, 8-9 
weeks old. Animals were injected intraperitoneally (i.p.) with 50 millions PBMCs.  
 
 
4.1 Newborn Rag2
-/-
 -chain-/- immunodeficient mice  
 
Newborn Rag2
-/-
 -chain-/- immunodeficient animals (n=33) were sublethally irradiated 
one day after birth and injected intrahepatically with 10-20 millions of human PBMCs 
the following day.  
Among treated animals, 67% (22/33) died between 15-20 days after intrahepatically 
injection; in 45% (5/11) of live treated animals the 27.1±0.5% of total blood cells 
expressed human CD45 at high levels 
 
4 weeks after injection, and this phenotype lasted 
about 6 months. These human cells were CD3
+
 (31.3±0.3% of total blood cells) CD4
+
 
(14.3±3.4% of total blood cells) and CD8
+
 (17.4±2.5% of total blood cells). No CD19
+
, 
CD56
+
 or CD14
+
 cells were detectable in the blood (Figure 8).  
Immunohistochemistry showed relevant differences only in the spleen and lung of 
treated mice versus untreated (Figure 9 and 10): the presence of human CD20
+
 B cells 
and CD3
+
, CD4
+
 and CD8
+
 T cells infiltrates into the spleen and lung was assessed in 
all treated mice, expecially near blood vessels. These cells were also CD138
+
, a marker 
of mature B cells. These lymphocytes were polyclonal, as shown by k and λ markers 
(data not shown), and theywere highly proliferative as shown by an increase in the 
number of Ki67
+
 cells.  
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Figure 8: Cytofluorimetric analysis of peripheral blood of Rag2-/- -chain-/- mice 4 weeks after 
intrahepatic PBMCs injection at the age of newborn: untreated mouse (left column) and mouse -
irradiated and injected intrahepatically with PBMCs (right column). Histograms show a representative 
case of treated and reconstituted newborn Rag2
-/-
 -chain-/- mice compared to untreated. Fluorescence 
values are expressed in absorbance units (a.u.). 
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Figure 9: Spleen from a representative case among Rag2-/--chain-/-mice -irradiated and injected 
intrahepatically with PBMCs at newborn age, four weeks after injection. A) 1-2: H&E staining of spleen 
specimen from: untreated mouse (1; 100× magnification) and treated mouse (2; 200× magnification) B) 
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(a-f) immunohistochemical analysis of spleen from a treated mouse (2): staining with CD20 (a; 200× 
magnification), CD138 (b; 400× magnification), CD3 (c; 200× magnification), CD4 (d; 100× 
magnification), CD8 (e; 100× magnification) and Ki67 (f; 400× magnification) markers. Bars represent 
250 μm.  
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Figure 10: Lung from a representative case among Rag2-/--chain-/-mice -irradiated and injected 
intrahepatically with PBMCs at newborn age, four weeks after injection:  A) H&E staining of lung 
specimen from (1-2): untreated mouse (1; 40× magnification) and treated mouse (2; 100× magnification); 
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B) (a-f)Immunohistochemical analysis of lung from a treated mouse (2) with: CD20 (a; 40× 
magnification), CD138 (b; 400× magnification), CD3 (c; 400× magnification), CD4 (d; 100× 
magnification), CD8 (e; 400× magnification) and Ki67 (f; 200× magnification) markers. Bars represent 
250 μm for 100×, 200× and 400× magnifications and 500 μm for 20× and 40× magnifications. The figure 
shows a representative case of different reconstituted newborn Rag2-/- -chain-/- mice. 
 
 
We finally evaluated the presence of Graft versus Host Disease (GvHD) in treated mice 
by direct observation of animals during the experiments and by immunohistochemical 
analysis of different organs (data not shown). Only one treated mouse displayed clear 
symptoms of Graft versus Host Disease (GvHD) (i.e.: severe weight loss, hunched 
posture, ruffled furr and reduced mobility). All the other treated animals did not develop 
detectable symptoms. Accordingly, immunohistochemistry analysis did not indicate any 
infiltrate of human inflammatory cells in skin, gut and liver. Unfortunately, this analysis 
could not be performed in the single symptomatic mouse, due to its premature and 
sudden death not allowing collection of material for histology). 
 
 
4.2 Adult Rag2
-/-
 -chain-/- immunodeficient mice  
 
Three months-old adult mice (n=8) were injected i.p. with -50 millions of human 
PBMCs. Among them, one group (n=6) was -irradiated (200-300-600 Gy) the day 
before PBMCs injection, whilst a second group (n=2) was not -irradiated. -irradiation 
with 600 Gy resulted lethal, whilst the other doses did not. -irradiation did not appear 
fundamental for reconstitution: no differences in engrafment of human cells were found 
in -irradiated mice compared to mice not -irradiated. All the PBMCs-injected adult 
animals showed low mortality after reconstitution. Another group of adult animals 
(n=6) was injected i.p. with Percoll gradient-separated human lymphocytes from 
healthy donors.  
Four weeks after injection, the presence of cells of the human immune system was 
evaluated in peripheral blood and organs of treated mice.  
Peripheral blood of all treated mice showed very low levels of human CD45
+
 cells 
(3.75±0.3% of total blood cells), CD3
+
 cells (3.45±0.3% of total blood cells), CD4
+
 
cells (1.85 ±0.2% of total blood cells) and CD8
+
 cells (1.55±0.6% of total blood cells). 
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No CD19
+
, CD56
+
 and CD14
+
 cells were detectable (Figure 11). 
Immunohistochemistry of lymphoid and other organs showed relevant differencies only 
in spleen and lung of treated mice versus untreated mice (Figure 12 and 13): the 
presence of human CD20
+
 B cells and CD3
+
, CD4
+
 and CD8
+
 T cells infiltrates into the 
spleen and lung was assessed in all treated mice, expecially near blood vessels. CD138
+
 
B cells, more numerous in the lung than in the spleen, were polyclonal, as shown by k 
and λ markers (data not shown), and they were highly proliferative, as shown by an 
increase in the number of Ki67
+
 cells (Figure 11). Finally, reconstituted adult mice did 
not show evidences or symptoms of GvHD by direct observation of animals during the 
experiments and by immunohistochemical analysis of different organs (data not shown). 
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Figure 11: Cytofluorimetric analysis of peripheral blood of not-irradiated Rag2-/- -chain-/- mice 4 weeks 
after injection at adult age of human PBMCs or human Percoll-separated lymphocytes: untreated mouse 
(left column), mouse injected i.p. with PBMCs (central column) and mouse injected i.p. with 
lymphocytes only (right column). Histograms show a representative case of different treated newborn 
Rag2-/- -chain-/- mice. Fluorescence values are expressed in absorbance units (a.u.). 
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Figure 12: Spleen from a representative case among Rag2-/--chain-/-mice injected i.p.  with PBMCs at 
adult age, four weeks after injection. A) (1-2) H&E staining of spleen specimen from: untreated mouse 
(1; 100× magnification) and mouse injected i.p. with PBMCs (2; 40× magnification); B) (a-f) 
Immunohistochemical analysis of spleen from a treated mouse with human CD20 (a; 200× 
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magnification), CD138 (b; 200× magnification), CD3 (c; 200× magnification), CD4 (d; 200× 
magnification), CD8 (e; 400× magnification) and Ki67 (f; 400× magnification) markers. Bars represent 
250 μm for 100×, 200× and 400× magnifications and 500 μm for 40× magnification.  
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Figure 13: Lung from a representative case among Rag2-/--chain-/-mice injected i.p. with PBMCs at 
adult age, four weeks after injection: A) (1-2) H&E staining of lung specimen from: not-treated mouse (1; 
100× magnification) and mouse injected i.p. with PBMCs (2; 100× magnification); B) (a-f) 
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Immunohistochemical analysis of lung of a injected mouse with human CD20 (a; 100× magnification), 
CD138 (b; 40× magnification), CD3 (c; 100× magnification), CD4 (d; 100× magnification), CD8 (e; 
200× magnification) and Ki67 (f; 200× magnification) markers. Bars represent 250 μm for 100× and 
200× magnifications and 500 μm for 40× magnification.  
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IV. Results 
SECTION II 
 
4.3 Immunophenotype of PaCa-44, PT-45, PANC-1 and PANC-2 pancreatic 
cancer cells 
 
 
The human primary pancreatic adenocarcinoma-derived PaCa-44, PT-45, PANC-1 and 
PANC-2 cell lines, HLA-A*0201 homozygous, were chosen for the present study 
because they express relevant amounts of the HLA-A*0201 molecule and thus could 
function as targets of CTLs from HLA-A*0201 donors (Figure 14).  
Because important for the cross-talk with T cells (Yang S. and Schlom J. , 2009), the 
expression of MHC-II, adhesion and  co-stimulatory molecules was also monitored. The 
ICAM-1 and LFA-3 adhesion molecules appeared differently expresses in these cell 
lines: PaCa-44 and PT-45 express only LFA-3, whilst PANC-1 and PANC-2 express 
also ICAM-I. On the contrary, MHC-II, B7-1 and B7-2 molecules were not expressed at 
all (Figure 14). 
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Figure 14: Cytofluorimetric analysis of PaCa-44, PT-45, PANC-1 and PANC-2 cancer cells after indirect 
immunofluorescence staining with monoclonal antibodies specific for HLA-A2 and MHC-II molecules, 
and after direct immunofluorescence staining with anti-human B7-1, B7-2, ICAM-1 and LFA-3 
molecules, as indicated at the top of each line. The different cell lines are indicated to the left of each 
horizontal series of histograms. Red histograms indicate the fluorescence of isotype controls or CTRL 
FITC (fluorescence of each sample treated only with the secondary monoclonal antibody). Fluorescence 
values are expressed in absorbance units (a.u.). Images were analyzed by FlowJo application. 
 
 
4.4 Hyperthermia induced apoptosis followed by secondary necrosis in 
PaCa-44, PT-45, PANC-1 and PANC-2 pancreatic cancer cells in vitro 
 
As recently described by Brusa et al., hyperthermia treatments at 56°C or by UVC 
lamp, inducing secondary necrosis, renders prostate tumor cells highly palatable to iDCs 
and able to activate T cell responses, because necrotic tumor cells release DAMPs 
molecules, like HSP70 and HMGB-1. To test if the conditions of hyperthermia 
treatments used in vitro by Brusa et al. could be applied also to pancreatic cancer, we 
performed hyperthermia experiments with the PaCa-44, PT-45, PANC-1 and PANC-2 
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human pancreatic tumor cell systems. The induced state of apoptosis-necrosis of tumor 
cells was evaluated by FACS analysis using Annexin-V–FITC and propidium iodide-PE 
staining kit (see 3.3). We could recognize alive cells (Ann V
-
/PI
-
), cells in primary 
necrosis (Ann V
-
/PI
+
), cells in early apoptosis (Ann V
+
/PI
-
), and cells in secondary 
necrosis (Ann V
+
/PI
+
) (Figure 15A). 
The treatment of PaCa-44, PT-45, PANC-1 and PANC-2 cells in water bath at 56°C 
induced apoptosis followed by secondary necrosis (Ann V
+
/PI
+
) in about 80-90% of 
treated cells already after 15 minutes and there was no difference for all the other time 
points (30 minutes, 1 hour, 2 hour). These results were confirmed after 20 hours of 
incubation at 37°C (Figure 15B). Reported results of hyperthermic treated cells for all 
the time points were statistically significant compared to untreated cells, except for 
PANC-2 treated for 15 minutes and incubated at 37°C 4 hours after the treatment (P  
0.01; P  0.001) (Figure 15B). 
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Figure 15: Treatments of PaCa-44, PT-45, PANC-1 and PANC-2 tumor cells at 56°C for 15, 30, 60 and 
120 minutes. A) Cytofluorimetric analysis of PaCa-44 cells treated at 56°C at different time points and 
incubated 4 hours at 37°C after the treatments (images were analyzed by FlowJo application). The data 
shown are from one representative experiment out of three with similar results. B) Histograms with 
statistical analysis of all pancreatic cancer cell lines treated at 56 °C and incubated for 4 or 20 hours at 
37°C before immunofluorescence staining with AnnV/PI kit. Each histogram indicates the mean value of 
three different experiments with standard deviation of the results. The differences between necrotic cells 
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after 56°C treatment and untreated cells were statistically significant (*= P  0.05; **=P  0.01; ***=P  
0.001). 
 
 
In all the UVC treatments (time of exposure: 10, 20, 30 and 60 minutes) the fraction of 
necrotic cells ranged between 27% and 56%, depending on cell line and time of UVC 
exposure, and increased to 50-85% after 20 hours of incubation at 37°C (Figure 16). As 
shown, after UVC treatment and 4 hours incubation, there was an increase of 
AnnV
+
/PI
+
 cells, which was directly correlated with increasing UVC exposure time. 
This trend was maintained also 20 hour after treatments, except for PT-45 cells that 
displayed a high fraction of necrotic cells already after 10 minutes of UVC exposure, 
indicating that PT-45 cells are more sensitive to UVC exposure than the other tumor 
cell lines. 
Statistical analysis confirmed the significance of the reported results for all cancer cell 
lines, especially for the longest UVC exposure time (30 minutes and 1 hour) after 4 
hours incubation, and for all time of exposure after 20 hours of incubation (P  0.05 for 
PANC-1; P  0.01 for PaCa-44; P  0.001 for PT-45 and PANC-2). 
The exposure time of 1 hour for both treatments at 56°C and with UVC was chosen for 
the following experiments. 
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Figure 16: Treatments of PaCa-44, PT-45, PANC-1 and PANC-2 tumor cells by UVC lamp for 10, 20, 
30 and 60 minutes. A) Cytofluorimetric analysis of PaCa-44 cells treated by UVC at different time points 
and incubated 4 hours at 37°C after the treatments (images were analysed by Flow Jo application). The 
data shown are from one representative experiment out of three with similar results. B) Histograms with 
statistical analysis of all pancreatic cancer cell lines treated by UVC and incubated for 4 or 20 hours at 
37°C before immunofluorescence staining with AnnV/PI kit. Each histogram indicates the mean value of 
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three different experiments with standard deviation of the results. The differences between necrotic cells 
after UVC treatment and untreated cells are statistically significant (*= P  0.05; **=P  0.01; ***=P  
0.001). 
 
 
Then tumor cell death was analyzed comparing 56°C and UVC treated cells with the 
same cancer cells -irradiated for 260 minutes (13000 cGy) or treated with Gemcitabine 
for 72 hours (final concentration: 1M) (Figure 17A). In all pancreatic cancer cells, the 
treatment able to induce the highest fraction of necrotic cells was the hyperthermic one 
(P  0.01 or  P  0.001 versus not-treated cells; P  0.05 or P  0.01 versus irradiated 
cells and cells treated with Gemcitabine for all cell lines) even if also the percentage of 
necrotic cells after exposure to UVC was significantly increased compared to untreated 
or irradiated cells or Gemcitabine-treated cells (P  0.05 or P  0.01for all cell lines), 
and it was comparable to 56°C incubation.  
PaCa-44, PT-45, PANC-1 and PANC-2 cancer cells were resistant to -irradiation with 
no differences between 4 and 20 hours of incubation (Figure 17B). 
Treatment with Gemcitabine (1M) for 72 hours evidenced differences between cancer 
cell lines. PaCa-44 and PT-45 were more sensitive to this chemotherapeutic agent than 
PANC-1 and PANC-2: the fraction of treated necrotic cells significantly increased 
compared to untreated cells (P  0.05 for PaCa-44; P  0.01 for PT-45), although this 
fraction was significantly lower than that that found after hyperthermic treatment . For 
PaCa-44 and PT-45, Gemcitabine was also responsible of an increase of the fraction of 
early apoptotic AnnV
+
/PI
-
 cells, as reported in Figure 17A. On the other hand, PANC-1 
and PANC-2 were resistant to the chemotherapeutic agent and the fraction of necrotic 
cells was comparable to untreated cells (Figure 17B). 
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Figure 17: Treatments of PaCa-44, PT-45, PANC-1 and PANC-2 tumor cells by -irradiation source for 
260 minutes (13000 cGy), at 56°C for 1 hour, by UVC for 1 hour and with Gemcitabine (final 
concentration: 1μM). A) Cytofluorimetric analysis of PaCa-44 cells treated with the different conditions 
reported above and incubated 4 hours at 37°C after the treatments (images were analysed by FlowJo 
application). The data shown are from one representative experiment out of three with similar results. B) 
Histograms with statistical analysis of all pancreatic cancer cell lines treated with the different conditions 
reported above and incubated 4 or 20 hours at 37°C before immunofluorescence staining with AnnV/PI 
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kit. Each histogram indicates the mean value of three different experiments with standard deviation of the 
results. The differences between necrotic cells after different treatments and untreated cells are 
statistically significant (*= P  0.05; **=P  0.01; ***=P  0.001). 
 
 
4.5 Hyperthermia at 56°C and UVC exposure treatments induced release of 
DAMP molecules (HMGB-1 and HSP-70) in PaCa-44, PT-45, PANC-1 and 
PANC-2 pancreatic cancer cells in vitro 
 
We analyzed the release of DAMPs in the supernatants of treated and untreated PaCa-
44, PT-45, PANC-1 and PANC-2 cells, after 4 or 20 hours of incubation at 37°C. 
The levels of HMGB-1 and HSP-70, not present or present at poor levels in the 
supernatants of untreated cells, were especially increased after UVC exposure. The 
treatment at 56°C increased the release of HMGB-1, but not of HSP-70, as detected by 
ELISA specific assays (Figure 18 and Figure 19). 
As shown in Figure 18, there was a statistically significant HMGB-1 release after 
exposure of the tumor cells to UVC (about 100-200 ng/ml; P < 0.01 for PaCa-44 and 
PT-45 cells compared to untreated cells; about 100-150 ng/ml; P < 0.05 for PANC-1 
and PANC-2 cell lines compared to untreated cells). Hyperthermia at 56°C induced an 
increase of HMGB-1 release, although this was not statistically significant. 
When cells were treated at 56°C, there was no difference if they were incubated for 4 or 
20 hours at 37°C; whereas, after UVC exposure, HMGB-1 release was increased after 
20 hours of incubation. 
The levels of HMGB-1 in the supernatants of -irradiated cells or cells treated with 
Gemcitabine were comparable to untreated cells. The highest amounts of HMGB-1 
molecule were detected in cell lysates (about 270 ng/ml; P < 0.01 for PaCa-44, PT-45, 
PANC-1 and PANC-2 compared to untreated cells). 
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Figure 18: ELISA assay for the quantification of HMGB-1 protein in the supernatants or lysates of PaCa-
44, PT-45, PANC-1 and PANC-2 cells. We evaluated untreated cells (NT) and  cells treated at 56°C for 1 
hour, with UVC for 1 hour, after -irradiation at  13000 cGy or treatment with Gemcitabine (1μM) for 72 
hours. For 56°C and UVC treatments, we analyzed supernatants of cells incubated at 37°C for 4 or 20 
hours after treatments. Cell lysates were used as positive controls. Each histogram indicates the mean 
value of three different experiments with standard deviation of the results. The statistically significant 
differences in HMGB-1 release between treated and untreated cells are indicated at the top of the 
histograms (*= P  0.05; **=P  0.01; ***=P  0.001). 
 
 
Figure 19 shows that HSP-70 was released in the supernatant only after UVC exposure 
(about 75-90 ng/ml; P < 0.01 for PaCa-44, PT-45, PANC-1 and PANC-2 cells 
compared to untreated cells; P < 0.05 for PANC-1, 4h after treatment compared to 
untreated cells), and after 20 hours of incubation at 37°C . 
On the contrary, incubation at 56°C did not induce HSP-70 release after either 4 or 20 
hours of incubation, in all four cell lines. 
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The levels of HSP-70 in supernatants of -irradiated cells or cells treated with 
Gemcitabine were comparable to untreated cells. Cell lysates released a statistically 
significant quantity of HSP-70 molecule for all cell lines (about 80-100 ng/ml; P < 0.01 
for PaCa-44, PT-45, PANC-1 and PANC-2 compared to untreated cells). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: ELISA assay for the quantification of HSP-70 protein in the supernatants or lysates of PaCa-
44, PT-45, PANC-1 and PANC-2 cells. We compared untreated cells (NT) to cells treated at 56°C for 1 
hour, with UVC for 1 hour, -irradiation at 13000 cGy or with Gemcitabine (1μM) for 72 hours. For 56°C 
and UVC treatments, we analyzed supernatants of cells incubated at 37°C for 4 or 20 hours after 
treatments. Cell lysates were used as positive controls. Each histogram indicates the mean value of three 
different experiments with standard deviation of the results. The statistically significant differences in 
HSP-70 release between treated and untreated cells are indicated at the top of the histograms (*= P  
0.05; **=P  0.01; ***=P  0.001). 
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4.6 Hyperthermia reduced the release of TGF- in PaCa-44, PT-45, PANC-1 
and PANC-2 pancreatic cancer cells in vitro 
 
Similarly to many cancer cells, pancreatic cancer cells secreted the immunosuppressive 
cytokine TGF- (Figure 20): the ELISA assay detected 200-350 pg/ml of TGF-β in the 
colture medium from PaCa-44 and PANC-2 48 hrs cultures,  and about 500-600 pg/ml 
in the colture medium from PT-45 and PANC-1 48 hrs cultures. TGF-β secretion 
appeared inhibited after -irradiation at 13000 cGy or incubation at 56°C or UVC 
exposure for 1 hour, but not after treatment with Gemcitabine. Cells treated with 
Gemcitabine released levels of TGF- comparable to those of untreated cells. These 
results were statistically significant for PaCa-44 (P < 0.05 compared to untreated cells) 
and PANC-1 (P < 0.05 compared  to untreated cells) but not for PT-45 and PANC-2: 
PT45 secretion showed high variability among experiments, and PANC-2 did not 
release relevant levels of TGF-β even when untreated, compared to the other cell lines. 
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Figure 20: ELISA assay for the quantification of TGF- protein in the supernatants of PaCa-44, PT-45, 
PANC-1 and PANC-2 cells. We evaluated untreated cells (NT) and cells treated at 56°C for 1 hour, with 
UVC for 1 hour, after -irradiation  at 13000 cGy or treated with Gemcitabine (1μM) for 72 hours. For 
56°C and UVC treatments, we analyzed the supernatants of cells incubated at 37°C for 4 or 20 hours after 
treatments. Each histogram indicates the mean value of two different experiments with standard deviation 
of the results. The statistically significant differences in TGF-β release between treated and untreated 
cells are indicated at the top of the histograms (*= P  0.05; **=P  0.01; ***=P  0.001). 
 
 
4.7 Hyperthermia-treated PaCa-44, PT-45, PANC-1 and PANC-2 tumor 
cells improved maturation of DCs compared to untreated cells 
 
During their progression from immature to mature state, DCs up-modulate CD80 (B7-1) 
and MHC-II molecules and express CD83, the DCs-specific maturation marker. iDCs 
were incubated with PaCa-44, PT-45, PANC-1 and PANC-2 tumor cells, untreated or 
treated with hyperthermia, UVC or Gemcitabine as described above (see 3.4 and 3.7). 
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After 24 hours, they received the maturation cytokine cocktail TNF-, IL-1, IL-6 and 
PGE2. The effect of incubating the tumor with iDCs was studied before the addition of 
cytokines (Figure 21) and after the addition of cytokines, 48 hours later (72 hours after 
the beginning of DCs-tumor mixed culture) (Figure 22). 
Twenty four hours following the beginning of the experiments and before addition of 
maturative cytokines, DCs were stimulated with untreated and treated tumor cells.  
As shown in Figure 21, before the addition of maturation cytokines, DCs up-modulated 
CD80 and CD83 molecules expression when they were stimulated with untreated and 
treated tumor cells, compared to iDCs . 
Noteworthy, the DCs phenotype was strongly affected after 48 hours of co-culture in 
presence of maturation cytokines with untreated cancer cells, as indicated by the 
reduction of CD80, CD83 and MHC-II molecules; whereas hyperthermia-treated cells 
and UVC treatment were able to increase DCs maturation, although not at the same 
levels of mDCs (P < 0.05 compared to mDCs). Gemcitabine treatment affected DCs 
maturation 48 hours after the addition of maturation cytokines (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Hystograms with mean +/- SD percentages of CD80, CD83 and MHC-II molecules of iDCs 
co-cultured with PaCa-44, PT-45, PANC-1 and PANC-2 untreated cells (NT) and of the same cells 
IV RESULTS- Section II 
 
85 
 
treated at 56°C for 1 hour, with UVC for 1 hour or with Gemcitabine (1μM) 24 hours after the beginning 
of co-cultures and before addition of maturative cytokines TNF-, IL-1, IL-6 and PGE2. iDCs alone 
were used as control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Hystograms with mean +/- SD percentages of CD80, CD83 and MHC-II molecules of DCs 
co-cultured with PaCa-44, PT-45, PANC-1 and PANC-2 untreated cells (NT) and of the same cells 
treated at 56°C for 1 hour, with UVC for 1 hour or with Gemcitabine (1μM) 48 hours after addition of 
maturative cytokines TNF-, IL-1, IL-6 and PGE2. mDCs alone were used as control. 
 
 
4.8 Hyperthermic treatments increased tumor phagocytosis by iDCs 
 
PaCa-44, PT-45, PANC-1 and PANC-2 cells treated at 56°C and with UVC were then 
tested for their capability to induce phagocytosis by iDCs. The phagocytosis assay was 
performed as described in 3.8: before the treatments, pancreatic cancer cells were 
stained with PKH26-PE, that recognize cell membrane, and, after 24 hours of co-
incubation with iDCs, the cells were stained with anti-CD80-APC, specific for DCs 
(Figure 23). DCs stained with CD1a-FITC were also analyzed by fluorescence 
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microscopy (Figure 24). As can be appreciated in Figure 23 and 24, 56°C and UVC 
treatments resulted in an increased percentage of phagocytosed PaCa-44, PT-45, 
PANC-1 and PANC-2 cells compared to untreated cells, even if no statistically 
significant effect was induced on tumor uptake by any treatments. In Figure 23, 
phagocytosis by iDCs is indicated in the upper-right quarter of each panel, as double-
labelled cells on total CD80
+
 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Uptake of dying tumor cells by iDCs. Cytofluorimetric analysis of the phagocytosis 
experiments performed with DCs, labelled with CD80-APC, and PaCa-44, PT-45, PANC-1 and PANC-2 
cells, labelled with PKH26-PE and treated at 56°C or with UVC. The data shown are from one 
representative experiment out of three with similar results. Images were analyzed by FlowJo application. 
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Figure 24: Uptake of dying tumor cells by iDCs. Fluorescence microscopy on co-cultures of DCs, 
labelled with CD1a-FITC, and PaCa-44, labelled with PKH26-PE, not-treated (A; 200× magnification) or 
treated by UVC (B, 200× magnification; C, 400× magnification; D, 600× magnification). Nuclear 
staining was obtained by DAPI (4',6-diamidino-2-phenylindole). Data obtained with cells treated by UVC 
were confirmed also for 56°C and all cell lines used. Bars represent 50 μm. The data shown are from one 
representative experiment out of two with similar results. 
 
 
 
 
 
 
 
 
IV RESULTS- Section II 
 
88 
 
4.9 Generation of CTLs was increased by loading of iDCs with hyperthermic 
treated tumor cells 
 
Four hours after hyperthermic treatments, PaCa-44, PT-45, PANC-1 and PANC-2 cells 
were incubated with iDCs. Twenty hours later, iDCs were exposed to the maturation 
cytokine cocktail to optimize their antigen-presenting activity and after 48 hours they 
were used as stimulators for autologous lymphocytes. Stimulation was repeated twice. 
Cytofluorimetric analysis of co-cultures showed an increased percentage of CD8
+
 and 
CD4
+
 T cells when lymphocytes were co-cultured with DCs loaded with necrotic cells 
(obtained by both 56°C incubation or UVC treatment), while DCs loaded with untreated 
cells did not stimulate efficiently lymphocytes and the number of CD8
+
 and CD4
+
 T 
cells decreased rapidly after repeated stimulations (Figure 25).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Cytofluorimetric analysis of the co-cultures of lymphocytes with DCs loaded with PaCa-44 
not-treated (NT) or treated at 56°C or by UVC, six days after the first stimulation (A) or six days after the 
second stimulation (B). Similar results were obtained for PT-45, PANC-1 and PANC-2 cancer cells. The 
results shown are from one representative experiment out of four with similar outcome. 
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4.10 Lymphocytes stimulated by DCs loaded with hyperthermic-treated 
tumor cells produced a specific anti-tumor response 
 
Five days after the last stimulation, the induction of a specific anti-tumor response was 
assessed by IFN- ELISA assays on supernatants of co-cultures (Figure 26) and by 
standard cytotoxicity assays with stimulated lymphocytes against untreated cancer cells 
as targets (Figure 27). 
Human IFN- ELISA assays showed an increase of IFN- release when lymphocytes 
were stimulated with DCs loaded with treated cancer cells, in particular when DCs were 
loaded with UVC-treated necrotic cells (P < 0.01 for PaCa-44 and PT-45 versus not-
stimulated autologous lymphocytes). In the case of treatment at 56°C, only lymphocytes 
stimulated with DCs loaded with PT-45 released a statistically significant level of IFN- 
versus not-stimulated autologous lymphocytes (P < 0.01). Interestingly, also untreated 
PT-45 cells seemed to stimulate an effective immune response even if it was not 
statistically significant. Lymphocytes stimulated with UVC or 56°C-treated PANC-1 
and PANC-2 cancer cells showed an increase of IFN- release compared to 
lymphocytes alone or lymphocytes stimulated with DCs plus not-treated cancer cells, 
although it was not statistically significant. Nevertheless, the variability of the response 
was donor-dependent (Figure 26). 
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Figure 26: Human IFN-levels in the supernatants of cross-priming co-cultures for PaCa-44, PT-45, 
PANC-1 and PANC-2 cells, 5 days after the last stimulation. Each histogram indicates the mean value 
with standard deviation of the results relative to three different experiments. The statistically significant 
differences in IFN-release between treated and untreated cells are indicated at the top of the histograms 
(**=P  0.01). 
 
 
Cytotoxicity assays revealed the induction of low levels of cytotoxic activity against 
PaCa-44 and PT-45 cancer cell lines, when lymphocytes were stimulated with DCs 
loaded with UVC-treated cells, but not against PANC-1 and PANC-2 cell lines. 
Lymphocytes stimulated with DCs loaded with cells treated at 56°C did not show 
appreciable target-specific cytotoxic activity (Figure 27).  
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Figure 27: Cytotoxic response against PaCa-44, PT-45, PANC-1 and PANC-2 cancer cells of 
lymphocytes stimulated twice with DCs loaded with not treated or treated tumor cells at 56°C or with 
UVC. The percentage of 51Cr release is on the ordinate. All experiments were performed with a 50:1 
effector:target ratio. Each histogram indicates the mean value with standard deviation of the results 
relative to two different experiments. 
 
 
4.11 Adoptive transfer of human T-lymphocytes stimulated in vitro with DCs 
loaded with UVC-treated PaCa-44 and PT-45 tumor cells did not inhibit 
tumor growth, but increased overall survival 
 
The results of the in vitro cytotoxicity assays described above indicated that PaCa-44 
and PT-45 cells might be better targets for CTLs than PANC-1 and PANC-2. Therefore 
they were chosen to test the in vivo efficacy of a protocol of curative immunotherapy.  
Rag2
-/-
 -chain-/- immunodeficient mice (n=4/ group) were injected s.c. with PaCa-44 or 
PT-45 tumor cells (2.5x10
6
 cells/ mouse), and, when s.c. tumor was palpable, they were 
adoptively transferred with T-lymphocytes (5x10
6
cells/mouse) stimulated twice in vitro 
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by DCs from same donor, loaded with necrotic tumor cells. When tumor diameter was 
1-1,5 cm, mice were sacrified and peripheral blood, tumor and organs were collected for 
FACS analysis and immunohistochemistry. 
All mice developed palpable tumors during the experiment, that did not decrease after 
immunotherapeutic treatments.  
 
 
4.11.1 PaCa-44 
 
Overall survival (OS) for animals inoculated with PaCa-44 was between 12-22 days 
after tumor inoculation (median OS: day +17) in control animals (n=4) and it was 
comparable to OS of animals treated by ACT performed either i.v. or i.p. with T cells 
stimulated with DCs loaded with 56°C-treated and i.v. with UVC-treated PaCa-44 cells 
(median OS: day + 17, day +18 and day + 18 respectively). We observed an increase, 
although not statistically significant, in median OS only when mice received an i.p. 
injection of T-lymphocytes stimulated with DCs loaded with UVC-treated PaCa-44 
cells (17-36 days; median OS: day +27) (Figure 28). 
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Figure 28: OS in PaCa-44 curative immunotherapy. OS of Rag2-/- -chain-/- mice injected s.c. with 
2.5x106 PaCa-44 tumor cells, followed, when tumor s.c. was palpable, by i.v. or i.p. adoptive transfer of 
5x106 T-lymphocytes stimulated twice in vitro by DCs loaded with necrotic tumor cells by 56°C 
incubation or UVC exposure, as indicated. 
 
 
We observed a trend towards slower tumor growth in the groups of mice that received 
immunotherapeutic approach with T-lymphocytes stimulated in vitro with DCs loaded 
with 56°C or UVC-treated PaCa-44 cells with respect to control mice injected with w.t. 
tumor cells only. In particular, i.v. ACT with T-lymphocytes stimulated with UVC-
treated PaCa-44 cells and i.p. ACT with T-lymphocytes stimulated with 56°C-treated 
PaCa-44 cancer cells seemed to work better in term of decrease of tumor growth rate, 
although these differencies were not statistically significant. PaCa-44 mean volume at 
day +10 was 0.48±0.17 cm
3
 (n=4) for i.v. ACT with UVC-treated PaCa-44 cells, and 
0.48±0.05 cm
3
 (n=4) for i.p. ACT with 56°C-treated PaCa-44 cells. By comparison, 
mean volume at the same time point was 0.67 ±0.15 cm
3
 (n=4) in the case of control 
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mice (PaCa-44 injected alone). All other immunotherapeutic approaches resulted in 
mean tumor volumes comparable with control mice (Figure 29) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Tumor growth rate in PaCa-44 curative immunotherapy. Tumor growth rate after tumor onset 
(mean volumes) of Rag2-/- -chain-/- mice injected s.c. with 2.5x106 PaCa-44 tumor cells, followed by i.v. 
or i.p. adoptive transfer of 5x106 T-lymphocytes stimulated twice in vitro by DCs loaded with necrotic 
tumor cells. 
 
 
Treated mice did not show any human CD45
+
 cells detectable in peripheral blood (data 
not shown). Immunohistochemistry showed no human CD45
+
 cells in their spleens, 
except for one mouse among those injected with lymphocytes stimulated with DCs 
loaded with UVC-treated PACA-44 cells (n=1/4), showing low CD45+ human cells. No 
human CD45
+
 cells were found in tumor masses of all mice, either ACT-treated and 
ACT-untreated control mice. We also observed inflammation and tumor metastases in 
lungs of some ACT-untreated control and ACT-treated mice, using an anti-cytokeratin-
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8 antibody, specific for epithelial cells, but it seemed to decrease after 
immunotherapeutic approach. (Figure 30).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Immunohistochemical analysis of tumor mass (a-c) and of spleen (d-f), with human CD45 
marker, and of lung (g-i) with cytokeratin-8 (CK-8) of: a control mouse injected s.c. with w.t. PaCa-44 
tumor (mass: a; 100× magnification; spleen: d; 100× magnification;¸lung: g; 400× magnification), a 
mouse injected with w.t. tumor followed by i.p.ACT with lymphocytes stimulated twice in vitro by DCs 
loaded with 56°C-treated tumor cells (mass: b; 100× magnification; spleen: e; 100× magnification;¸lung: 
h; 40× magnification) and mouse injected with w.t. tumor followed by i.p. ACT with lymphocytes 
stimulated twice in vitro by DCs loaded with UVC- treated tumor cells (mass: c; 100× magnification; 
spleen: f; 200× magnification;¸lung: i; 20× magnification) No differencies were observed between i.p. or 
i.v. injected mice. Bars represent 250 μm for 100×, 200× and 400× magnifications and 500 μm for 20x 
and 40× magnifications. The figure shows a representative case of different treated Rag2-/- -chain-/- mice. 
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4.11.2 PT-45 
 
OS for animals inoculated with PT-45 was between 43-78 days after tumor inoculation 
(median OS: day +61) in control animals (n=4). We observed an increase in median OS 
when mice received immunotherapeutic approaches, in particular i.v. ACT with T cells 
stimulated with DCs loaded with 56°C-treated PT-45 cells (43-99 days; median OS: day 
+71) and i.p. ACT with T-lymphocytes stimulated with UVC-treated PT-45 cells (60-98 
days; median OS: day +79). This OS increase was not statistically significant. (Figure 
31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: OS in PT-45 curative immunotherapy. OS of Rag2-/- -chain-/- mice injected s.c. with 2.5x106 
PT-45 tumor cells, followed, when tumor s.c. was palpable, by i.v. or i.p. adoptive transfer of 5x106 T-
lymphocytes stimulated twice in vitro by DCs loaded with necrotic tumor cells by 56°C incubation or 
UVC exposure, as indicated. 
. 
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We observed a statistically significant decrease in tumor growth rate in the groups of 
mice that received ACT with T-lymphocytes stimulated in vitro with UVC-treated PT-
45 cells (either i.v or i.p; P  0.01 and P  0.001 at day +20, respectively), compared to 
control mice injected only with w.t. tumor cells. PT-45 mean volume at day +20 was 
0.22±0.2 cm
3
 (n=4) for i.v. ACT with T-lymphocytes stimulated in vitro with UVC-
treated PT-45, and 0.13±0.11 cm
3
 (n=4) for i.p. ACT with T-lymphocytes stimulated in 
vitro with UVC-treated PT-45. By comparison, mean volume at the same time point 
was 0.59 ±0.2 cm
3
 (n=4) in the case of control mice injected with PT-45 without ACT. 
ACT with T-lymphocytes stimulated in vitro with PT-45 incubated at 56°C did not 
reduce tumor growth respect to control mice and, when T-lymphocytes were injected 
i.p., tumor growth rate increased more rapidly than in control mice (Figure 32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Tumor growth rate in PT-45-specific  curative immunotherapy Tumor growth rate after tumor 
onset (mean volumes) of Rag2-/- -chain-/- mice injected s.c. with 2.5x106 PT-45 tumor cells, followed by 
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i.v. or i.p. adoptive transfer of 5x106 T-lymphocytes stimulated twice in vitro by DCs loaded with 
necrotic tumor cells. 
 
 
ACT-treated mice did not show any human CD45
+
 cells in peripheral blood, spleen and 
tumor masses (data not shown). 
We also observed PT-45 tumor metastases and, in some cases, inflammation in lungs of 
control and treated mice, but they seemed to decrease after immunotherapeutic 
approaches (data not shown).  
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V. Discussion 
 
This study is focused on the establishment of a preclinical model of immunodeficient 
mouse to study pancreatic cancer immunotherapy. Mouse models harbouring human 
cells or tissues (also called “humanized mouse models”) have been very helpful to 
investigate underlying immunological mechanisms in human biology, immune-
mediated diseases, transplantation and cross-talk between cancer and immune system. 
Although the “humanized mouse” is a difficult field of research, it still remains a 
relevant model for preclinical studies. 
The original project was to develop patients-derived “humanized mouse” bearing 
human immune system from pancreas adenocarcinoma patients starting from bone 
marrow-derived CD34+ immune-precursor cells, engraft the autologous tumor and 
study the interactions between tumor and immune system and eventually try to develop 
systems to enhance tumor-specific immune responses and inhibit tumor-mediated 
immunosuppressive mechanisms. So far we could not obtain bone marrow neither from 
these patients or from healthy donors, therefore we focused this study to analyze: 
1. the possibility of engraftment of human PBMCs and purified T-lymphocytes in 
newborn or adult immunodeficient mice and 
2. the development of an immunotherapeutic approach for pancreatic cancer in 
immunodeficient mice bearing growing human pancreas tumors. 
 
In our mouse facilities we developed a colony of C57BL/6-Rag2
-/-
  chain-/- mice. These 
animals lack T and B cells, they have a compromised innate immunity and, even if a 
small number of NK cells remains, they do not function correctly, and according to 
current literature, should offer technical advantages over SCID recipients, because they 
appear to accept more readily human PBMCs, show improved reconstitution rates and 
reject more reliably human transplants (Abele-Ohl, 2010).  
Newborn immunodeficient mice were -irradiated after birth and injected 
intrahepatically with PBMCs. As already described (see Results 4.1), C57BL/6-Rag2
-/-
  
chain
-/-
 mice displayed high mortality at newborn age: 67% (22/33) animals died 
between 15-20 days after intrahepatically injection. In addition only 45% (5/11) of live 
treated animals showed human CD45+, CD3+/CD8+ or CD3+/CD4+ cells in peripheral 
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blood 
 
4 weeks after injection. B-lymphocytes were always absent in the blood of these 
mice, according to literature, as well as cells of myelo-monocyte origin (Mosier et al., 
1988; van Rijn et al.,2009; Abele-Ohl et al., 2010). These mice showed also the 
presence of T and B cells in the spleen and in the lungs (Figure 9 and 10 of Results-
section I). Interestingly, B cells were absent in peripheral blood, but they were detected 
in spleen. 
In adult mice, -irradiated or not, receiving an intraperitoneal injection of PBMCs or T-
lymphocytes, engrafment of human cells appeared independent from -irradiation in 
both cases. These mice did not display any mortality following PBMCs injection, but 
peripheral blood of all treated mice showed very low levels of human CD45
+
 cells 
(3.75±0.3% of total blood cells, vs 27.1±0.5% found in mice treated at newborn age). 
Nevertheless immunohistochemical analysis detected positive staining for human T and 
B cells in the spleen of these mice injected at adult age (Figure 12 and 13 of Results-
section I), similarly to mice injected at newborn age, suggesting that delivery of PBMCs 
at adult age allows T and B cells colonization of secondary lymphoid organs but it is 
poorly permissive for blood circulation of these cells.  
Therefore engrafment of human cells from PBMCs resulted more effective when human 
PBMCs were inoculated in newborn animals, even if mortality of newborns following 
PBMCs inoculation was close to 70%.  
The proliferation capacity of engrafted human T and B cells was analyzed and 
confirmed by the expression of the Ki67 marker. Ki-67 is an excellent marker to 
determine the growth fraction of a given cell population, because it is a nuclear protein 
associated with and maybe necessary for cellular proliferation (Scholzen T et al., 2000). 
Surprisingly, while other organs were normal and similar to those of untreated mice, 
lungs appeared highly repopulated by human T and B cells, with characteristics close to 
those T and B cells found in the spleen. These results were reproducible for all treated 
newborn and adult mice. Moreover, mice did not present any symptoms of pain, even if 
there was an acute state of pulmonary inflammation. The presence of human cells T and 
B in lungs is possible because engrafted cells can reach the different organs through 
blood and lungs are the largest filter of peripheral blood. The reasons for the 
accumulation of human lymphocytes in the lungs are still unclear, since these mice were 
not injected intravenously with human PBMCs, but intrahepathically or 
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intraperitoneally. It may depend on the activation of a mechanism like that of the 
CD11b+CD103+ DCs secreting Th2-stimulating chemokines, where these DCs, 
resident in both spleen and lung, are able to act across inter-species barriers and recruit 
and stimulate Th2 cells (del Rio ML et al., 2010). This observation, even if it needs to 
be better analyzed may be extremely interesting and helpful for pre-clinical models of 
pulmonary inflammation and related diseases. The results described are referred to 
C57BL/6 Rag2
-/-
  chain-/- mice and they cannot be generalized to other 
immunocompromised mouse strains. However, for further studies, it could be very 
interesting to perform the same experiments with other immunocompromised mouse 
strains. 
The second part of the work presented was focused on the development of an 
immunotherapeutic approach for pancreatic cancer. 
The aim of antigen-specific active antitumor immunotherapy is to break tolerance 
against tumor-associated antigens (TAAs) by presenting them in the context of co-
stimulatory signals on antigen presenting cells, as dendritic cells (DCs). 
The immunogenic potential of dying tumor cells received great attention for both its 
importance in enhancing T cell-directed immunotherapy and its indication of the best 
immunogenic source for ex vivo TAA DCs loading (Lake et al., 2005; Nowak et al., 
2006). Apoptosis is generally regarded as tolerance-inducing cell death (Voll et al., 
1997 Steinman et al., 2000) but it was recently reported to be immunogenic in vitro and 
in vivo (D‟Hooghe et al., 2007); moreover, necrotic death has long been considered 
highly immunogenic because of the danger signals it conveys (Gallucci et al., 1999;  
Sauter B et al., 2000). 
DCs capture necrotic tumor cells, process them and present the relevant T-cell antigen 
epitope in the context of both class I and class II MHC, thus allowing the cross-priming 
of CD8
+
 T lymphocytes (Banchereau et al., 1998). 
We focused our attention on the activation of a pancreas adenocarcinoma-protective 
immune response using the human PaCa-44, PT-45, PANC-1 and PANC-2 pancreatic 
tumor cell lines made necrotic by means of hyperthermia treatment at 56°C or UVC 
exposure, because they could represent a vaccination approach translatable to clinical 
protocols. 
V DISCUSSION 
 
102 
 
The use of 4 different cell lines is important to point out different responses that could 
be obtained with different human pancreatic tumor clones. 
According to Brusa et al. (Brusa et al., 2009), treatment of PaCa-44, PT-45, PANC-1 
and PANC-2 cells at the temperature of 56°C caused secondary necrosis in about 90% 
of cell population already after a 15 minutes incubation, while UVC treatment needed 
longer exposure times (1 hour). Necrotic cell death induced by 56°C heating or by UVC 
treatment produced better results in terms of percentage of necrotic cells than -
irradiation or treatment with Gemcitabine, actually the gold standard treatment for 
pancreatic cancer. 
Cell death by hyperthermia or UVC generates necrotic material producing factors that 
induce DCs activity of antigen processing and cross-priming of CTLs (Shi et al., 2007). 
Necrotic cell death induced by 56°C heating or by UVC exposure determines a 
remarkable release outside the cell of molecules named “danger associated molecular 
pattern” (DAMPs) HSP70 and HMGB-1. When released outside tumor cells, these 
molecules promote increased expression of MHC-peptide complexes, reduction of 
iDCs-maturation time, reversion of the suppressive action of tumor cells on CTL cross-
priming and increased expression of the chemokine receptor CCR7, responsible of DCs 
migration to lymph nodes (Brusa et al., 2008 and 2009). 
In addition, necrotic cell death induced by 56°C heating or by UVC treatment reduces 
the release of TGF- molecule, involved in the immunosuppressive mechanisms of 
tumor escape. Not only necrotic PaCa-44, PT-45, PANC-1 and PANC-2 pancreatic 
cancer cells result more palatable to iDCs, but also mDCs loaded with necrotic tumor 
cells are able to activate an immune response when they are co-cultured with autologous 
T-lymphocytes.  
UVC treatment resulted more effective than 56°C heating in the induction of tumor-
specific immune response, and the best results in vitro were obtained with PaCa-44 and 
PT-45 tumor cells, while we were not able to obtain a specific cytotoxic T response for 
PANC-1 and PANC-2, even if high levels of IFN- were detectable in co-culture 
supernatants. The different results obtained with any single cell line need to be further 
investigated comparing the different expression profiles of immune- and cancer-related 
molecules of each cell line, in order to unveil the possible mechanisms that make one 
pancreatic cancer more sensitive to immunotherapeutic approach with respect to another 
one. 
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The in vitro results led us to investigate this immunotherapeutic approach also in vivo, 
using protocols of curative immunotherapy. Curative immunotherapy with PT45 and 
PaCa-44 produced some encouraging results. 
Rag2
-/-
 -chain-/- mice were injected s.c. with tumor cells, followed by i.v. or i.p. 
adoptive transfer of T-lymphocytes stimulated twice in vitro by DCs loaded with 
necrotic tumor cells. All treated animals developed tumors, but mice treated with 
curative immunotherapy showed a higher OS and a lower tumor growth rate compared 
to animals that did not receive the immunotherapeutic approach, but were injected with 
w.t. tumors. The effect was more evident when UVC-treated tumor cells were used. The 
difference was statistically significant only for tumor growth rate using UVC-treated 
PT45 cells versus control mice.  
 
The critical points of this model are: 1) the low number of T-lymphocytes that can be 
injected in mice, obtained by in vitro restimulation; 2) the low number of mice for each 
groups (n=4) due to the low number of activated lymphocytes obtained; 3) the donor–
dependent variability of the T-lymphocytes response against pancreatic tumors. In these 
experiments, PT-45 cancer cells resulted more immunogenic than PaCa-44 cells, 
expecially when treated with UVC. The route of injection (i.v. or i.p.) of human 
lymphocytes does not seem to compromise the efficacy of the immunotherapeutic 
approach. Interestingly, we did not find human lymphocytes in the blood and tumors of 
ACT-treated mice, while we found CD45+ human cells in the spleen of one ACT-
treated mouse where lymphocytes were stimulated with DCs loaded with UVC-treated 
PACA-44 cells (n=1/4). Tumor metastasis and inflammation were present in lungs of 
some control and treated mice but they were more evident in control mice compared to 
treated mice. These data suggest that the ACT treatment may be able to impair 
metastatization, but more experiments are needed on a more extended number of 
animals to validate this hypothesis.  
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